Embed Size (px)
Citation preview
1
1
Revised: 2/2/06
CURRICULUM VITAE
JOSEPH H. FRIEDMAN, MD
PERSONAL INFORMATION Home Address: 52 Bluff Road
Barrington, RI 02806 Business Address: NeuroHealth
227 Centreville Road Warwick, RI 02886
Business Telephone: 401-921-4203 Date of Birth: November 16, 1948 Place of Birth: New York City Citizenship: U.S.A. Marital Status: Married, three children EDUCATION 1965-1969 University of Chicago, Mathematics, B.A. 1971-1973 Washington University, St. Louis, M.A.( Mathematics) 1975-1978 Columbia University College of Physicians and Surgeons, M.D. POSTGRADUATE TRAINING 1978-1979 Internship (Internal Medicine) Mt. Sinai Hospital New York, NY 1979-1982 Residency (Neurology), Neurological Institute of New York PROFESSIONAL LICENSES
2
2
Rhode Island 5976 Massachusetts 72735 (inactive) BOARD CERTIFICATIONS 1979 Diplomate National Board of Medical Examiners 1983 American Board of Neurology and Psychiatry Certified in Neurology HOSPITAL APPOINTMENTS 1982-1996 Chief, Division of Neurology, Roger Williams General Hospital,
Providence, Rhode Island 1984-1996 Consulting Staff, Institute for Mental Health, Cranston, Rhode Island 1982-1986 Consulting Staff, Veterans Administration Medical Center, Providence,
Rhode Island 1987-1996 Consulting Staff, U.E. Zambarano State Hospital, Chepachet, Rhode
Island 1988-1989 Acting Medical Director, Physical Therapy Department Roger Williams
General Hospital, Providence, Rhode Island l990-Present Consulting Staff, Butler Hospital, Providence, Rhode Island 7/93-Present Consulting Staff, Rhode Island Hospital, Providence, Rhode Island 1996-2005 Chief, Division of Neurology, Memorial Hospital of Rhode Island,
Pawtucket, Rhode Island ACADEMIC APPOINTMENTS 1982 Assistant Professor, Department of Medicine, Brown University Medical
School 1985-1986 Acting Chief, Division of Neurology, Brown University Program in
Medicine 1989-1994 Associate Professor, Department of Clinical Neurosciences, Brown
University Program in Medicine 1994-2005 Professor, Department of Clinical Neurosciences, Brown University
School of Medicine
3
3
1996-Present Adjunct Professor, School of Pharmacy, University of Rhode Island 2004 Neurology Instructor (April 2004). Chainama Medical Sciences College,
Lusaka, Zambia 2004 Visiting Professor, Dept of Medicine, University Teaching Hospital, Lusaka, Zambia 2005- Clinical Professor, Dept of Clinical Neuroscience, Brown University Medical School OTHER APPOINTMENTS 1969-1971 Mathematics Instructor, Men's Teacher Training College, Bimbilla, Ghana
(Peace Corps Volunteer) 1971-1973 Teaching Assistant, Department of Mathematics, Washington University 1973-1974 Assistant Programmer, Department of Biophysics and Physiology
Washington University 1974 Assistant Programmer, Biology Department, Columbia University 1983 Medical Board, New England Dystonia Society 1983-1997 Neurology Consultant, Brown University Student Health Services 1984-1989 Executive Board, Parkinson's Disease Referral and Information Center of
Rhode Island 1984-1996 Neurologist, Neuropsychiatric Research and Training Center, Rhode
Island Institute for Mental Health (Eleanor Slater Hospital). 1984-1989 President, Rhode Island Chapter American Parkinson's Disease
Association 1985-1989 Neurology Faculty, Merck, Sharpe & Dohme Pharmaceuticals 1987-Present Neurology Faculty, Novartis Pharmaceuticals 1989-Present Neurology Faculty, DuPont Pharmaceuticals 1986-Present Member, Parkinson's Study Group 1988 Physician-Rhode Island Special Olympics 1988-1994 Physician Volunteer-Travelers' Aid Van for the Homeless
4
4
1988-Present Director, Brown University Parkinson's Disease and Movement Disorder Unit
1991-Present Clinical Director, APDA Parkinson's Disease Referral and Information
Center 1992-Present Editorial Advisory Board, Neurology Reviews 1994-1995 (Volunteer) Neurology Consultant, Providence Ambulatory Health Care
Centers 1991-1996 Neurology Consultant, Center for Human Services, New Bedford, MA. 1997-present Neurology Faculty – Pharmacia/Ingleheim Boehringer Corporation 1998-present Neurology Faculty – Roche/GlaxoSmithKline Pharmaceuticals 1998-present Neurology Faculty - Astra Zeneca Pharmaceuticals 1998-2001 Editor, Living Well June 98-Dec. 98 Associate Editor-in-Chief, Medicine and Health Rhode Island Jan 99-Present Editor-in-Chief, Medicine and Health, Rhode Island 2000-2002 Executive committee Parkinson’s Study Group 2004-2005 Parkinson’s Study Group (PSG) Nominating Committee 2005 Member Ad Hoc NINDS Grant Review Committee: CoEnzyme Q10 in
Parkinson’s Disease. R01 NS050324-01A1 2004-present Parkinson Study Group credentials committee 2005-present Parkinson Disease Guideline Dissemination Committee, American
Academy of Neurology 2006-present Movement Disorders Task Force on Psychosis Rating Instruments in PD 2006-present Elected to AAN Movement Disorders Section Executive Committee UNIVERSITY COMMITTEES 1985 Chairman, Search Committee for Assistant Professor of Medicine,
Division of Neurology, Roger Williams General Hospital 1985 Member, Search Committee for Chair of Neurosurgery, Brown University
and Rhode Island Hospital
5
5
1985 Member, Search Committee for Pediatric Orthopedist, Brown University and Rhode Island Hospital
1986 Chief, Search Committee for full time neurologist, Veterans
Administration Hospital, Providence, Rhode Island 1986 Member, Brown University Committee on Maternity/Paternity Leave for
Clinical Faculty in Medical Program 1986 Member, Ad Hoc Planning Committee on Physical Medicine and
Rehabilitation, Brown University, Providence, Rhode Island 1986 Member, Search Committee for Pediatric Orthopedist, Brown University
and Rhode Island Hospital 1987 Chair, Search Committee for full time neurologist, Roger Williams
General Hospital, Providence, Rhode Island 1988 Member, Search Committee for Pediatric Neurosurgeon, Brown
University and Rhode Island Hospital 1988 Member, Search Committee for Chief of Neurology, Pawtucket Memorial
Hospital, Pawtucket, Rhode Island 1989-1994 Member, Reappointment and Promotions Committee for the Department
of Clinical Neurosciences, Brown University Providence, Rhode Island 1994-present Chair, Reappointment and Promotions Committee for the Department of
Present Clinical Neurosciences, Brown University Providence, Rhode Island
1993 Member, Search Committee for Staff Neurologist at Rhode Island
Hospital, Providence, Rhode Island l995 Member, Search Committee for Gamma Knife Neurosurgeon at Rhode
Island Hospital, Providence, Rhode Island 1995 Member, Search Committee for Staff Spinal Neurosurgeon at Rhode
Island Hospital, Providence, Rhode Island. 1996 Member, Search Committee for Staff Neuroimmunologist at Rhode Island
Hospital, Providence, Rhode Island. 1998 Ph.D. Dissertation Committee for Emily Pickett, Department of Cognitive
Sciences and Linguistics, Brown University, Providence, RI.
6
6
HOSPITAL COMMITTEES 1986-1990 Pharmacy and Therapeutics Committee, Roger Williams General Hospital,
Providence, Rhode Island 1986-1987 Ad Hoc Committee on Improving Medical Record Systems 1992-1994 Medical Staff Executive Committee, Roger Williams Medical Center 1996-2001 Graduate Medical Education Committee, Memorial Hospital of Rhode
Island HOSPITAL TEACHING ROLES 1990-Present Director, Neurology Grand Rounds. Brown University 1990-Present Supervision of neurology residents in Movement Disorder Clinic each
week. Feb. 1993 Site Director, Bio 315F (Medical Student long-term clinic) UNIVERSITY TEACHING ROLES 1982-1983 Clinical Pharmacology (School of Medicine) 1982-1984 Neuroscience II (School of Medicine) 1983-1989 Chair, Neurology Section for Brown University Board Review Course in
Internal Medicine 1984-1996 Director, Monthly Elective in Consultative Neurology (School of
Medicine), 304F Roger Williams General Hospital/Brown University 1987-Present Neuroscience 262 (School of Medicine), Lecturer and discussion group
leader 1987-1988 Introduction to Neural Science (Guest lecturer) 1987 Course Director, Symposium on Brain Implantation in Parkinson's Disease
Rhode Island Hospital/Roger Williams General Hospital/Brown University
1988 Course Director, Symposium on Current Concepts of Parkinson's Disease,
Brown University 1990-1996 Director, Neurology Resident Rotation at Roger Williams Medical Center.
7
7
1991 Guest Lecturer, Psychology 50, Brown University 1991-Present Lecturer, PGY III conference Psychiatry Resident Seminar Series
(Neurobehavior in Parkinson’s disease) 1991-Present Lecturer, PGY IV conference Psychiatry Resident Seminar Series (Neurobehavior in Parkinson’s disease) 1992 Course Director and Lecturer: Parkinson's Disease and Movement
Disorders for Primary Care Physicians. 1992 Course Director and Lecturer. New and Experimental Approaches to the
Treatment of Parkinson's Disease. 1993-1994 Lecturer for Brown Learning Connection 9/93-10/94 Weekly neurology teaching rounds, Medical Psychiatry Unit, Rhode
Island Hospital. 1994-Present Human Pathology PHP 561 (for Pharm. D. fellows) Univ. of Rhode Island
School of Pharmacy 1995-1996 Monthly Neurology Teaching conference, Center for Human Services,
New Bedford, MA 1996-Present Brown University Biomed 373: The Neurological Exam, Physical
Diagnosis; second year. 1996- Present Brown University Biomed 351: The Neurological Exam, Physical
Diagnosis; third year. 1997-Present Neurology Conference, Internal Medicine and Family Medicine Residency
Programs, Memorial Hospital of Rhode Island 2003-Present Neurology rotation: geriatric Internal Medicine and Geriatric Psychiatry
Fellowships (Brown Unviersity) HONORS/AWARDS 1968-1969 Murphy Scholarship for Extracurricular Activities (Music). U of Chicago l978 Harold Brown Scholarship in Tropical Medicine Lawrence J. Durante
Scholarship. Columbia University College of Physicians and Surgeons
8
8
l982-l983 "Teacher of the Year"-Elected by the Medical Housestaff, Roger Williams Medical Center
l986 & l987 Visiting Professor, Department of Neurology, University of Vermont l990 Honorary Member of Executive Board, Rhode Island Parkinson's
Association l990 M.A. ad eundem, Brown University 1991 Rhode Island Parkinson's Support Association Distinguished Service
Award l992 "Point of Light" award from President George Bush for volunteer work on
the Traveler's Aid Medical Van l993 Guest Editor of Rhode Island Medical Journal devoted to Movement
Disorders. 1995 Co-Chair, Session on Pharmacology of Parkinson's disease, American
Academy of Neurology, April, l995, Seattle, WA. 1995 Co-Chair, Platform presentations on Neuropharmacology of Parkinson's
disease. American Academy of Neurology Annual Meeting. May, l995. 1996-1999 Member, Rhode Island Medical Society, Editorial Board of Medicine &
Health/Rhode Island. 1997 Guest Editor, Health and Medicine, Rhode Island; issue devoted to stroke. 1997 Co-Chair, Platform presentations on Clozapine in movement disorders.
The 4th Congress of the European Society for Clinical Neuropharmacology. December 1-4, 1997.
1998 Fellowship, American Academy of Neurology. 1999 Named in Who’s Who in America, 2000 edition 2000 Accepted as life time member of National Registry of Who’s Who 2000
Edition (137634) 2001 Accepted as life time member of National Registry of Who’s Who 2001
Edition (137635) 2001 Accepted as a member of The National Registry of Who’s Who in the
World. 2001 Edition.
9
9
2001 Accepted as a member of The National Registry of Who’s Who in Science
and Engineering. 2001 Edition. 2001 Council on International Nontheatrical Events (CINE). Golden Eagle
Award for video “EPS” 2001. 2002 Guest editor – Lancet Neurology Network 2002 Peer nomination into the book “Guide to Top Doctors,” published by the
Center for the Study of Services (CSS), and on the website: www.GuideToTopDoctors.org.
2002 Peer nomination into the Internet based referral service “Best Doctors”.
www.BestDoctors.com. February 15, 2002 2002 Friedman, JH. Recognized in "Rhode Island Monthly" May 2002 for
being nominated as "Top Doc". May 2002. 2003 Chosen to be listed in The Rhode Island edition of Better Living
Magazine’s Best Doctors section. October 2002. www.betterlivingmagazine.com
2002 Friedman, JH. Providence Journal. Joseph H. Friedman, MD named in
"Best Doctors 2001-2002". This is a database containing names of doctors from across the country chosen as "Best" by their peers. www.bestdoctors.com
2004 World Federation of Neurology Teaching Fellowship in Zambia 2004 Guest Editor, The Journal of Clinical Psychiatry, devoted to Drug-
Induced Movement Disorders (Volume 65; Supplement 9) 2004 Dean’s Teaching Excellence Award, Brown University Medical School 2004 NIH ad hoc peer reviewer for grant submission on Coenzyme Q10 for
Early Parkinson’s disease. August 9, 2004 2004 Gold Eagle Award from CINE for videotape Recognizing Parkinsonism,
made with John Armstrong, Margaret Lannon. 2005 Selected as one of “America’s Top Physicians” in the `Guide to America’s
Top Physicians` 2005 Selected as one of Leading Health Professionals of the World. Intl
Biographical Centre, Cambridge, England.
10
10
2005 Best Doctors in America 2005-2006 (PIN # 132884) 2006 Psychosis Working Group for Movement Disorders Society SOCIETIES l980-l986 American Medical Association l980-Present American Academy of Neurology l986-Present Movement Disorders Society l993-Present American Neurological Association 1995-Present Rhode Island Neurological Association 1998-Present Rhode Island Medical Society CONSULTING l993-l994 Upjohn Pharmaceuticals l992-1998 Cytotherapeutics Inc. 1995-1998 Ingelheim Boehringer Pharmaceuticals 1996-1998 Lilly Pharmaceuticals 1998-1999 Pfizer Pharmaceuticals 1999-2000 Hoechst-Marion-Roussel Pharmaceuticals 1999-present Astra Zeneca Pharmaceuticals 1999-2001 Merck, KGa (Germany) Pharmaceuticals 1999-Present Novartis Pharmaceuticals 2000-2002 PPD Development Corporation 2000 YourDoctor.com 2001 Pharmstar, LLC 2003 UCB Pharma, Bristol Myers Squibb, Janssen Pharma 2003 Acadia Pharmaceuticals 2005 Biogenidec
11
11
12
12
JOURNAL REVIEWER ADIS CNS Drugs, American Academy of Neurology, American Hospital Formulary Service, Annals of Neurology, Arch Dis Childhood; Progress in Neuro-Psychopharmacology and Biological Psychiatry, Archives of Neurology, Clinical Neuropharmacology, Drugs and Aging, Epilepsia, Expert Opinion on Drug Safety, Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, Journal of the American Geriatrics Society, Journal of Consultation and Liason Psychiatry, Journal of Geriatric Psychiatry, Journal of Neural Transmission, Journal of Neurology, The Lancet Neurology, Neurosurgery & Psychiatry, Medical Letter Yearbook(section on Parkinson’s Disease),Movement Disorders, Neurology, Neuropsychopharmacology, New England Journal of Medicine, New York State Journal of Medicine, Parkinsonism and Related Disorders, Primary Psychiatry ABSTRACT REVIEWER
1998 Fifth International Congress of Parkinson’s Disease and Movement Disorders. October 1998, New York, NY
2005 American Academy of Neurology annual meeting 2006 EDITORIAL BOARD 1997-2003 Editor-in-Chief. Living Well. A magazine for people with Parkinson’s
Disease. 1998-present Neurology Reviews 1999-present Editor-in-Chief. Medicine & Health Rhode Island (RI State
medical journal) 2003-2006 Editorial Board. Movement Disorders 2004 Guest Editor, Journal of Clinical Psychiatry Supplement on Tardive Dyskinesia GRANT REVIEWS 1988, 1999 Veterans Administration Merit Grants 1995, 1996 Project Development Grants, Rhode Island Hospital 2002 Alzheimer’s Disease Association 2003 Michael J Fox Foundation 2004 United Kingdom PD Society 2005 Parkinson Study Group
13
13
PUBLICATIONS (peer reviewed) 1. Schultz G, Barry C, Friedman J, et al: Comparison of predicted and experimentally
determined secondary structure of adenylate kinase. Nature 1974;250:140-142. 2. Friedman J, Brust J, Challenor Y: Bilateral facial palsy associated with Steven-Johnson
Syndrome. Neurology 1979;29:1304-1306. 3. Haruda F, Friedman J, Ganti S, Hoffman N, Chutorian A: Reversal of organic mental
syndrome in sickle cell anemia by rapid exchange transfusion. Neurology 1981;31:1015-1016.
4. Friedman J, Brem H, Mayeux R: Global aphasia in multiple sclerosis. Ann Neurol
1983;13:222-223. 5. Friedman JH: Controversies in the Treatment of Parkinson's Disease. RI Med J
1981;68:461-463. 6. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, and Friedman JH: Validity
and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35:73-77.
7. Weinstein R, Herec D, Friedman JH: Hypotension due to glossopharyngeal neuralgia.
Arch Neurol 1985;43:90-92. 8. Friedman JH: Drug holidays in Parkinson's Disease: A brief review. Arch Int. Med
1985;145:913-915. 9. Lally E, Friedman JH, Kaplan S: Progressive myalgias and polyarthralgias in a patient
with myoadenylate deaminase deficiency. Arthritis and Rheumatism 1985;28:1298-1302. 10. Friedman JH, Feinberg S, Feldman RD: A neuroleptic malignant like syndrome due to L-
DOPA withdrawal. JAMA 1985;254:2792-2795 11. Friedman JH: Syndrome of diffuse encephalopathy due to non-dominant thalamic
infarction. Neurology 1985;35:1524-1526. 12. Friedman JH: A case of progressive hemichorea responsive to high dose reserpine. J Clin
Psychiatry 1986;47:149-150. 13. Friedman JH: Recent Research Advances in Parkinson's Disease. Part I: MPTP. RI Med J
1986;69(7)319-322. 14. Friedman JH: Recent Research Advances in Parkinson's Disease, Part II: Brain
Implantation Therapy. RI Med J 1986;69(8):361-363.
14
14
15. Friedman JH, Wagner RL: Akathisia: The syndrome of motor restlessness. American Family Physician 1987;35(2):145-149.
16. Friedman JH, Chuicchini I, Tucci J: Idiopathic Hypoparathyroidism with Extensive Brain
Calcification and Persistent Neurologic Dysfunction. Neurology 1987;37:307-309. 17. Friedman JH: Hemifacial Gustatory sweating Due To a Pancoast Tumor. Am J Med
1987;82:1269-1273. 18. Rafal RD, Friedman JH: Limb Dystonia in Progressive Supranuclear Palsy. Neurology
1987;37:1546-1549. 19. Friedman JH, Hollmann PA: Acetazolamide Responsive Hereditary Paroxysmal Ataxia.
Movement Disorders 1987;2(l):67-72. 20. Friedman JH, Kucharski TL, Wagner RL: Tardive Dystonia in a Psychiatric Hospital. J.
Neurol Neurosurg & Psychiatry 1987;50:801-803. 21. Kucharski LT, Friedman JH, Wagner RL: An investigation of the coexistence of
abnormal involuntary movements, parkinsonism and akathisia in chronic psychiatric inpatients. Psychopharmacology Bulletin 1987;23(l):215-217.
22. Rafal RD, Inhoff AW, Friedman JH, Bernstein E: Programming and complex motor
sequences in Parkinson's Disease. J Neurol Neurosurg and Psychiatry 1987;50:1267-1273.
23. Friedman JH, Max J, Swift R: Idiopathic Parkinson's Disease in a Chronic Schizophrenic:
Long Term Treatment with Clozapine and L-DOPA. Clin Neuropharm. 1987;10(5):470-475.
24. Rafal RD, Posner M, Friedman JH, Inhoff AW, Bernstein E: Orienting of visual attention
in progressive Supranuclear Palsy. Brain 1988;111(Pt 2):267-280. 25. Friedman JH: Azorean Disease (Joseph/Machado Disease) . RI Med J 1988;71(4):149-
153. 26. Friedman JH, Davies RL, Wagner RL: Neuroleptic Malignant Syndrome: The Results of
a Six Month Prospective Study of Incidence in a State Psychiatric Hospital. Clin Neuropharm 1988;2(4):373-377
27. Tzelepis GE, McCool FD, Friedman JH, Hoppin FG: Respiratory Muscle Dysfunction in
Parkinson's Disease. Am Rev Resp Dis 1988;138 (3):266-271. 28. Rafal RD, Friedman JH, Lannon MC: Preparation of Manual Movements in
Hemiparkinsonism. J Neurol Neurosurg & Psychiatry 1989;52 (3):399-402.
15
15
29. Friedman JH, Levy HL, Boustany R: Late Onset of Distinct Neurologic Syndromes in Galactosemic Siblings. Neurology 1989;39(5):741-742.
30. Friedman JH, Lannon MC: An Open Trial of Controlled Release Carbidopa/L-
DOPA (CR4 Sinemet) For the Treatment of Mild to Moderate Parkinson's Disease. Clinic Neuropharm. 1989;12(3):220-223.
31. Friedman JH Lannon MC: Clozapine for the treatment of psychosis in Parkinson's
Disease. Neurology 1989;39 (9):1219-1221. 32. Sandson T, Friedman JH: Spinal Cord Infarction. Report of Eight Cases and Review of
the Literature. Medicine 1989;68:282-292. 33. Friedman JH: Progressive Parkinsonism in Boxers. Southern Medical Journal
1989;82(5):543-546. 34. Lieberman P, Friedman JH, Feldman LS: Syntax Comprehension Deficits in Parkinson's
Disease. J Nervous and Mental Dis. 1990;178(6):360-365. 35. Friedman JH, Ambler M: A Case of Senile Chorea. Movement Disorders 1990;5(3):251-
253. 36. Friedman JH, Lannon MC: Clozapine-responsive tremor in Parkinson's disease.
Movement Disorders 1990;5(3):225-229. 37. Friedman JH: Primary Movement Disorders. RI Med J 1990;73 (2):69-73. 38. Rafal R, Friedman JH: Rostral Basilar Reversible Ischemic Neurologic Deficit in an HIV
Infected Patient with Cryptococcal Meningitis. Am J Med 1990;89(2):248-249. 39. Friedman JH: Drug induced movement disorders. Hospital Pharmacy. 1991;26:524-530. 40. Friedman JH: The Management of the Levodopa Psychoses. Clinical
Neuropharmacology 1991;14 (4):283-295. Review 41. McKnight P, Friedman JH. Torticollis in an adult due to cervical epidural abscess.
Neurology 1992;42:696-697. 42. Friedman JH: Rubral tremor induced by neuroleptic. Movement Disorders 1992;7
(3):281-282. 43. Friedman JH, Gordon N. ECT in Parkinson's Disease. Convulsive Therapy
1992;8(3):204-210. 44. Pueschl S, Friedman JH, Shetty T: Myoclonic Dystonia. Child Nervous System
1992;8(2):61-66.
16
16
45. Friedman JH, Ambler M: Progressive Parkinsonism Associated With Rosenthal Fibers:
Senile Onset Alexander's Disease. Neurology 1992;42:1733-1735. 46. Lieberman P, Friedman JH, Feldman LS: Speech Production, Syntax Comprehension and
Cognitive Deficits in Parkinson's Disease. Brain and Language 1992;43(2):169-189. 47. Friedman JH, Caley C: Does fluoxetine exacerbate Parkinson's disease? J. Clin
Psychiatry 1992;53:278-282. 48. Friedman JH, Weitberg A: Ataxia Without Telangiectasia. Movement Disorders
1993;8:223-226. 49. Friedman JH, Friedman H: Fatigue in Parkinson's Disease. Neurology
1993;43:2016-2018. 50. Friedman JH. Clozapine treatment of psychosis in patients with tardive dystonia: Report
of three cases. Movement Disorders 1994;9(3):321-324. 51. Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J et al: Pramipexole in Patients
with Early Parkinson's Disease. Clin Neuropharmacol. l995;18:338-347. 52. Rich S, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis
in Parkinson’s patients. J Clin Psychiatry 1995;56(12):556-569. 53. Friedman JH. Walking-Induced Parkinsonism Due to Presumed Idiopathic Normal
Pressure Hydrocephalus. Movement Disorders l996;ll(1):99-101. 54. Friedman J, Westlake R, Furman M: "Grievous Bodily Harm": Gamma Hydroxybutyrate
Abuse Leading to a Wernicke-Korsakoff Syndrome. Neurology 1996;46(2):469-471. 55. Friedman JH, Epstein M, Sanes J, Lieberman P, Cullen K, Lindquist C, Daamen M.
Gamma Knife Pallidotomy in Advanced Parkinson's Disease. Ann Neurol 1996;39:535-538.
56. Mikolivich DJ, Kinsella LH, Skowron G, Friedman JH, Sugar AM, et al. Aspergillus
meningitis in an immunocompetent adult successfully treated with itraconazole. Clin Inf Dis 1996;23(6):1318-9.
57. Friedman JH, Koller WC, Lannon MC, Benzotropine versus Clozapine for the treatment
of tremor in Parkinson’s disease. Neurology 1997;4(48):1077-1081. 58. Factor SA, Friedman JH. The emerging use of clozapine in the treatment of patients with
movement disorders. Movement Disorders 1997;12 (4):483-496.
17
17
59. Friedman JH. Machado-Joseph Disease/SCA3 responsive to Buspirone. Movement Disorders 1997;12 (4):613-614.
60. Lieberman A, Ranhowsky A, Korts, D, et al. Clinical evaluation of pramipexole in
advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology July 1997;49(1):162-168.
61. Shannon, KM, Bennett JP, Friedman JH: Efficacy of pramipexole, a novel dopamine
agonist as monotherapy in mild to moderate Parkinson’s disease. Neurology, 1997 49; (3):724-728.
62. Goren JL, Friedman JH. Yawning as an aura for an L-Dopa induced “on” in Parkinson’s
disease. Neurology. 1998; (50):823. 63. Trosch RM, Friedman JH, O’Brien C, et al. Clozapine Use in Parkinson’s disease: a
retrospective analysis of a large multi centered clinical experience. Movement Disorders. 1998; (13): 377-382.
64. Pickett ER, Kuniholm E, Protopapas A, Friedman JH, Lieberman P. Selective speech
motor, syntax and cognitive deficits associated with bilateral damage to the putamen and the head of the caudate nucleus: a case study. Neuropsychologia 1998;36(2):173-188.
65. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH. Levodopa
improves motor function without impairing cognition in mild non-demented Parkinson’s disease patients. Neurology 1998; 50 (5): 1327-31.
66. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the Treatment of
Drug-Induced Psychosis in Parkinson’s Disease. Mov Dis 1998;14(3):484-487. 67. Friedman JH, Goldstein S, Jacques C. Substituting Olanzapine for Clozapine. Clin Neuropharmacol.1998;21(5):285-288. 68. Friedman JH. Behavioral Dysfunction in Parkinson’s Disease. Clinical Neuroscience
Volume1998;5:87-93. 69. Rosenfeld M, Friedman JH. Catatonia Responsive to Lorazepam.Mov Dis.
1999;14(1):161-162. 70. Shetty N, Friedman JH, Kieburtz K, et al. The Placebo Response in Parkinson’s Disease.
Clinical Neuropharmacology 1999; (22):207-212. 70. Fernandez HH, Friedman JH. Atypical antipsychotics in movement disorder patients.
CNS Drugs. 1999; 11(6):467-483. 71. Myers DL, Arya LA, Friedman JH. Is Urinary Incontinence Different in Women with
Parkinson’s Disease? Int Urogynecology Journal 1999; 53:438-439.
18
18
72. Parkinson Study Group (Joseph H. Friedman first author). Low Dose Clozapine for The
Treatment of Drug-Induced Psychosis In Parkinson’s Disease. N Eng J med 1999; 340:757-763.
73. Fernandez HH, Friedman JH. Punding on L-DOPA. Mov Disorders 1999; 14:836-838. 74. Lapane K, Fernandez HH, Friedman JH. And The SAGE Study Group. Prevalence,
Clinical Characteristics, and Pharmacologic Treatment of Parkinson’s Disease in Residents in Long-Term Care Facilities. Pharmacoepidemiology 1999; 19:1321-1327
75. Fernandez HH, Friedman JH, Grace J, Beason-Hazen, S. Donepezil for Huntington’s
Disease Movement Disorders 2000; 15: 173-175 76. Friedman JH, Fernandez HH. The Nonmotor Problems of Parkinson’s Disease. The
Neurologist 2000; 6: (1) 18-27 77. Friedman JH, Factor SA. Atypical Antipsychotics in the Treatment of Drug-Induced
Psychosis in Parkinson’s Disease. Movement Disorders 2000; 15(2):201-211 78. Fernandez HH, Lapane KL, Ott BR, Friedman, JH. Gender Differences in the Frequency
and Treatment of Behavior Problems in Parkinson’s Disease. Movement Disorders 2000; 15:(3) 490-496
79. Fernandez HH, Lannon MC, Friedman JH, Abbott BP. Clozapine Replacement by
Quetiapine for the Treatment of Drug-Induced Psychosis in Parkinson’s Disease. Movement Disorders 2000 (Clinical/Scientific Notes) 15; (3):579-586
80. Tabamo REJ, Fernandez HH, Friedman JH, Simon DK. Young-Onset Parkinson’s
Disease: A Clinical Pathologic Description of Two Siblings. Movement Disorders 2000 (Clinical/Scientific Notes) 15;(4):744-746
81. Fernandez HH, Friedman, JH, Famiglietti EV. Probable Cornelia de Lange Syndrome
With Progressive Parkinsonism and Dystonia. Movement Disorders 2000 (Clinical/Scientific Notes) 15;(4): 749-751
82. Zawacki T, Friedman JH, Grace J, Shetty N. Cerebellar toxicity of cytosine arabinoside:
Clinical and neuropsychological signs. Neurology 2000 (Clinical/Scientific Notes) 55; (8): 1234
83. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K, and the Parkinson Study
Group. Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease: results of the 12-week open label extension in the PSYCLOPS trial. Movement Disorders 2001 Jan: 16 (1): 135-139.
19
19
84. Friedman, JH, Fernandez HH. Autopsy follow-up of a patient with schizophrenia and presumed idiopathic Parkinson’s disease. Clinical Neuropharmacology 2001 24;(2):120-121.
85. Goldstein S, Friedman JH, Marek K, et al. Hemiparkinsonism Due to a Midbrain
Arteriovenous Malformation: Dopamine Transporter Imaging. Mov Disord 2001;16(2):350-375.
86. Fernandez, H., Krupp, B., Friedman, JH. The course of tardive dyskinesia and
parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001; 56:805-807. 87. Friedman, JH. Permanent Cerebellar Toxicity of Cytosine Arabinoside (Ara C) in a
Young Woman. Mov Disord 2001; 16: 575-577 88. Brin, MF., Lyones, KE., Doucette, J., Adler, CH., Caviness, JN., Comella, CL.,
Dubinsky, RM., Friedman, JH. et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001;56:1523-1528.
89. Fernandez H., Friedman JH., Fischman, A., Noto, R., Lannon, MC. Is Altropane SPECT
More Sensitive to FluoroDOPA PET for Detecting Early Parkinson’s Disease? Altropane SPECT versus FluoroDOPA PET in Parkinson’s disease. Med Sci Monit, 2001;7:2-6.
90. Friedman, JH, Friedman, H. Fatigue in Parkinson’s Disease: A Nine-Year Follow-Up.
Movement Disorders 2001;16:1120-1122 91. Fernandez H., Rowena EJ., Tabamo,MD., David RR., Friedman JH. Predictors of
Depressive Symptoms Among Spouse Caregivers in Parkinson’s Disease. Movement Disorders 2001;16:1123-1125
92. Friedman, JH et al. Stroke induced by gamma knife pallidotomy: Autopsy result.
Neurology 2002;58:1695-1697 93. Cahn-Weiner DA, Grace J, Ott BR, Fernandez, HH, Friedman, JH. Cognitive and
Behavioral Features Discriminate Between Alzheimer’s and Parkinson’s Disease. Neuropsychiatry, Neurology, and Behavioral Neurology, 2002;15:79-87.
94. Fernandez HH., Trieschmann ME, Burke, MA, Friedman JH. Quetiapine for Psychosis
in Parkinson's Disease Versus Dementia With Lewy Bodies. J Clin Psychiatry 2002; 63: 513-515.
95. Zawacki TM., Grace J., Friedman JH., Sudarsky L. Executive and Emotional
Dysfunction in Machado-Joseph Disease. Movement Disorders 2002;17:1004-1010. 96. Walker RH, Friedman JH, Wiener J, et al. A family with tau P301L mutation presenting
with Parkinsonism. Parkinsonism & Related Disorders 2002; 9:121-123.
20
20
97. Friedman, JH. Presumed Rapid Eye Movement Sleep Behavior Disorder in Machado-
Joseph Disease (Spinocerebellar Ataxia 3). Mov Disord 2002;17:1350-1353. 98. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH.
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 2002;52:438-45.
99. Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson-sensitive populations.
J Geriatr Psychiatry Neurol. 2002;15(3):156-70 100. Fernandez HH, Friedman JH. Classification And Treatment of Tardive Syndromes. The
Neurologist 2003;9:16-27. 101. Garber CE, Friedman JH. Effects of fatigue on physical activity and function in patients
with Parkinson’s disease. Neurology 2003;60:119-1124. 102. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-Term
Outcome of Quetiapine Use for Psychosis Among Parkinsonian Patients. Movement Dis 2003;18:510-514.
103. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson’s disease
patients with psychosis. Neurology 2003;60:1576-61. 104. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of Psychosis in Parkinson’s
Disease. Safety Considerations. Drug Safety 2003:26:643-659. 105. Friedman JH, Fernandez HH, Trieschmann MM. Parkinsonism in a Nursing Home:
Underrecognition. J Geriatr Psychiatry Neurol 2004;17(1):39-41. 106. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for Drug-Induced
Psychosis in Parkinson Disease: Preliminary Experience. Cln Neuropharmacol 2004;27(1):4-5.
107. Fernandez HH, Lannon MC, Trieschmann ME, Friedman JH. Botulinum toxin type B for
gait freezing in Parkinson’s disease. Med Sci Monit 2004 Jul;10(7): CR 282-4. Epub 2004. June 29
108. Fernandez HH, Donnelly EM, Friedman JH. Long term outcome of clozapine use for
psychosis in Parkinson’s disease. Mov Disord 2004;19:831-3 109. Stern MB, Marek K, Friedman JH, et al. Double-blind, Randomized, Controlled Trial of
Rasagiline as Monotherapy in Early Parkinson’s Disease Patients. Mov Disord 2004;19(8):916-923
21
21
110. Fernandez HH, Friedman JH, Lansang CM, Factor SA, et al. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism Rel Disord 2004;10:439-41. .
111. Ready R, Friedman J, Grace J et al. Testosterone deficiency and fatigue in Parkinson’s
disease. J Neurol Neurosurg & Psychiatry. 2004;75:1323-26. 112. Al-Yacoub M, Fernandez HH, Friedman JH. Hemiballism from a parietal stroke in a
patient with Parkinson’s disease. Mov Disord 2004;19:986-988. 113. Friedman JH, Treischmann ME, Myers RH, Fernandez HH. Monozygotic twins
discordant for Huntington’s disease after seven years. Arch Neurol 2005;62:995-997. 114. D’Abreu A, Friedman J, Coskun J. Non-movement herald symptoms of Machado Joseph
Disease (SCA 3). Mov Disord. 2005;20:739-41
115. Murphy MA, Friedman JH, Tetrud JW, Factor SA. Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases. J Clin Neurosci. 2005;12:942-46.
116. Chou K, Messing S, Oakes D, …, Friedman JH. Drug Induced Psychosis in Parkinson’s
Disease: Phenomenology and Correlations Among Psychotic Rating Instruments. Clin Neuropharmacol 2005,28:215-19.
117. Borek LL, Friedman JH. Levodopa addiction in idiopathic Parkinson disease.
Neurology 2005;65:1508. (chosen as a“Highlight” for the issue) 118. Chou K, de Castillo Moro M, Friedman JH. Parkinsonian side effects of atypical antipsychotics in the elderly. Primary Care Psychiatry2005;12:65-71.
119.Scoggan KA, Friedman JH, Bulman DE. CACNA1A mutation in an EA-2 patient responsive to acetazolamide and valproic acid. Can J Neurosci. In Press.
120. Friedman JH, Goetz CG, Factor SA, et al. Low dose aripiprazole in the treatment of drug induced psychosis in Parkinson’s disease. Mov Disord. In Press.
121.Marsh L, McDonald WM, Cummings, et al. Provisional Diagnostic Criteria for Depression in Parkinson’s Disease: report of an NINDS/NIMH Work Group. Mov Disord. In Press
122.Borek LL, Amick M, Friedman JH. Non-motor aspects of Parkinson’s disease. CNS Spectrums. In Press.
123. Cherkes JK, Friedman JH. Negative toxicology screen in a patient abusing dextromethorphan. Neurology. In Press
124.Chou KL, Friedman JH. Are atypical antipsychotics associated with a reduced risk of developing parkinsonism? Nature Clinical Practice Neurology 2006;2:132-33.
125.
22
22
Chosen for inclusion in the Southeast Asia Edition of JAMA 2:63-66, 1986; translated into French for the French Edition of JAMA 11: 243-249, 1986 and translated into Japanese for the Japanese Edition of JAMA 7:77-80, 1986. Chosen for inclusion in Clinical Digest Chosen for inclusion as abstract in Annual Review of Neurosurgery 1990 Chosen for inclusion in Clinical Digest Series; Chosen for inclusion as an Abstract in the Bugamor Pharma Digest-The Netherlands. Parkinson/Alzheimer Digest 2:11-12,1992 *Abstracted and translated into Italian in Update on Parkinson's l994;3:37. Bugamor Press, Milano, Italy. Abstracted in Clinical Digest Chosen for inclusion in Clinical Digest Series (Parkinson/Alzheimer) Abstracted in Focus on Neurology 1997; 9: 43-44. Bugamor BV Press ▲Chosen for inclusion in Evidence Based Mental Health 1999; 2: 118 Chosen for inclusion in Transmitters, Receptors & Synapses 1999 OTHER PUBLICATIONS 1. Friedman JH, Pedley T, Carter S: Neurodiagnostic tests. Chapt. II in the syllabus for clinical
neurology. Columbia University College of Physicians and Surgeons, Department of Neurology, 1980.
2. Friedman J, Mates S: Praziquantel therapy for cysticercosis. Arch Neurology 1983;40:257.
Letter 3. Friedman J: Chronic pain in a thirty-five year old woman: Clini-Pearls 1985;8:9-10. 4. Feinsilver SH, Friedman JH, Rosen J: Respiration and sleep in Parkinson's Disease (Letter). J
Neurol Neurosurg and Psychiatry 1986;49:964. 5. Friedman JH, Feldman RG: Neuroleptic Malignant Syndrome: A Possible Endorphine
Mediated Hypothalamic Dysfunction. Reply from the Authors (Letter). JAMA 1986;255:2291-2292.
6. Friedman JH: Alternating unilateral jaw spasm due to metoclopramide. J. Neurol Neurosurg
and Psychiatry 1986;49:1463. (Letter to the Editor). 7. Buckler R, Friedman JH: Maprotiline induced ataxia (Letter). J Clin Psychopharmacology
1986;6(6):382-383. 8. Friedman JH: Parkinson's Disease (Commentary). New York State Journal of Medicine
1987;87:139-140. 9. Friedman JH, Liu HM, Spremulli E, Calabresi P: Distant metastases from a malignant
glioma. A case report (Letter). J Neurol Neurosurg Psychiatry 1987;50(2):237.
23
23
10. Birkhead R, Friedman JH: Hiccups and vomiting as presenting symptoms of multiple sclerosis. Case report (letter) . J Neuro Neurosurg Psychiatry 1987;50(2):232-233.
11. Friedman JH: Textbook Dispute. Letter to the Editor. Science 1987;236:655. 12. Book Review: Movement Disorders 2: Edited by C. David Marsden and Stanley Fahn.
Butterworths, International Medical Review Neurology (7]. New Eng J of Med 1987;316(25):1612.
13. Friedman JH: Neuroleptic Malignant Syndrome. Current Opinions in Neurology and
Neurosurgery. April, 1988. 14. Friedman JH: Book Review: Facial Dyskinesias. Edited by J. Jankovic et al. Movement
Disorders 1989;4(l):95-96. 15. Friedman JH: Neuroleptic Toxicity. Chapter in Current Therapy in Neurologic Disease-3, RT
Johnson (Ed.). 1990;pp3l7-322. 16. Friedman JH: Book Review: Principles of Neurology, Fourth Edition by R. Adams and M.
Victor. New England Journal Medicine 1990;32:704. 17. Friedman JF: Clozapine in Parkinson's Disease. NY Times (Letter). 10/90. 18. Friedman JF: Fetal Tissue Research is Necessary. Guest Editorial, Newport Daily News.
11/90. 19. Belliveau JF, Friedman JH, O'Leary GP, Guarrera D: Evaluation of increased copper levels
in the cerebrospinal fluid of Parkinson's disease patients. Proceedings of the International Symposium on Metal Ions in Disease. Metal Ions in Biology PH Collery, LA Poirier, M Manfait, et al (Eds.). John Libbey Eurotext, Paris, France. 1990;pp89-91.
20. Friedman JF: Clozaril in Parkinson's Disease. (Letter). New Eng J Med 1991;324:491. 21. Friedman JF: Clozapine and the Mandatory Monitoring System. 1991; N Eng J Med: p. 491. 22. Friedman JH, McKnight: Epidural Abscess and Torticollis. Reply from the authors.
Neurology 1992;42:2228. 23. Friedman JH: Neurology Supplements. Neurology 1992;42:1639. (Letter to the Editor). 24. Friedman JH: Driving and Parkinson's Disease. American Parkinson's Disease Association
Newsletter. Summer 1992. p.2. 25. Friedman JH. Clozapine in Parkinson's Disease. Neurology Forum 1992;3:3-15.
24
24
26. Friedman JH. Driving in Parkinson's Disease. American Parkinson's Disease Association Newsletter. December, l992.
27. Friedman JH, Duffy J. Pre-Test Board Review Questions in Neurology and Psychiatry.
Edition 2. 1992;McGraw Hill, NY. 28. Friedman JH: ECT in Parkinson's Disease. American Parkinson's Disease Association
Newsletter. Fall/Winter issue l992-l993. 29. Friedman: Involuntary Humming in Autopsy Proven PD. Movement Disorders. Letter to the
Editor. 1993;8(3):401. 30. Friedman JH. Akathisia with Clozapine. Biol Psychiatry. (Letter to the Editor)
1993;33:852-853. 31. Friedman JH, DeAngelis L, Calabresi P. A 38-year old woman with pressure headaches and
meningeal enhancement on MRI. Neurology Reviews l993;l (March/April):33. 32. Friedman JH, McKnight P. Non-dystonic torticollis. Reply from the Authors. Neurology
l993;43:1055. 33. Friedman JH, Cullen KC. Parkinson's Disease. A Guide for patients and their families.
Translated into Portuguese by Dr. DaSilva. American Parkinson's Disease Association. 1993.
34. Friedman JH. Spider Sightings. A Most Unusual Case. Cortlandt Forum. October, l993, p. 49 35. Friedman JH, Pseudo intoxication. A Most Unusual Case. Cortlandt Forum. l994;7:48. 36. Friedman JH. Clozapine treatment of psychosis in Parkinson's. J Clin Psychiatry (Letter)
1994;55(2):79. 37. Friedman JH. Punding on levodopa (Letter to the Editor). Biol Psychiatry 1994;36:350-351. 38. Friedman JH. Mianserin treatment of patients with psychosis induced by antiparkinsonism
drugs. European Archives of Psychiatry and Clinical Neurosciences 1996;246:106-107. (Letter to the Editor)
39. Friedman JH. Mohr JP, Gautier JC (eds). Guide to Clinical Neurology. N Eng J Med
1996;334(14):925. (Book review) 40. Friedman JH, Stone W. Delayed Onset Dystonia Secondary to Unilateral
Schizencephaly. Movement Disorders 1996;11(2):221-227. (Letter to the Editor). 41. Friedman JH, Goetz CG, Stebbins G. Psychotic Symptoms in Parkinson's Disease. (Letter to
the Editor) J Am Geriatrics Soc; 1997; 45: 252-253 (letter).
25
25
42. Friedman JH, Goldstein, SA. Olanzapine in the treatment of dopaminomimetic psychosis in
patients with Parkinson’s disease. Neurology 1998; (50) 4: 1195-1196. (Letter to the Editor). 43. Friedman JH. Movement Disorders edited by R Watts and WC Koller, McGraw-Hill
Ryerson, Ltd, 1998, Movement Disorders, 13 (2): 371-372. (Book Review) 44. Goren J, Friedman JH. Yawning as an aura for an L-Dopa-induced “on” in Parkinson’s
disease. Neurology. Reply to letters. Neurology 1998; (50) 3; 823. (Letter to the Editor) 45. Friedman JH, Ott BR. Should Risperidone Be Used in Parkinson’s Disease? Journal of
Neuropsychiatry and Clinical Neurosciences 1998;10(4):473-474. 46. Jacques C, Davies R, Friedman JH. Weight Gain in PD. The Journal of Neuroscience
Nursing. December 1998;30(6):342. (Letter to the Editor). 47. Friedman JH. The Creative Clinician: Rapid Onset Tardive Dyskinesia (“Fly
CatcheTongue”) in a Neuroleptically Naive Patient Induced by Risperidone. Medicine and Health, Rhode Island. 1998; 81(8):271-272.
48. Rosenfeld M, Friedman JH. Cervical Stenosis and Dystonic Cerebral Palsy. Movement
Disorders 1999;14(1): 194-195 (Letter) 49. Friedman JH. Intravenous Levodopa in Hallucinating Parkinson’s Disease Patients: High
Dose Challenge Does not Precipitate Hallucinations. Neurology. 1999;52:219. (Letter to the Editor).
50. Friedman JH. Enhanced fatigue during motor performance in patients with Parkinson’s
disease. Neurology 1999; 53:438-439. (Letter) 51. Friedman J, Goren J. Yawning in Parkinson’s disease. Reply from Authors. Neurology 1999
52(2):428. 52. Fernandez HH, Friedman JH, Centofanti JV. Benedikt’s Syndrome with Delayed-Onset
Rubral Tremor and Hemidsytonia: A Complication of Tic Douloureux Surgery. Mov Dis 1999;14(4):695-697. Letter to the Editor
53. Fernandez HH, Friedman JH. Carvedilol-Induced Myoclonus. Mov Dis 1999;14(4):703.
Letter to the Editor. 54. Friedman JH. Is Fatigue An Independent Symptom of Parkinson’s Disease? Neurology
Review. 1999; 7(4): 39. 55. Friedman JH. Low Dose Clozapine for the Treatment of Drug-Induced Psychosis in PD.
APDA Newsletter Summer 1999; p5.
26
26
56. Friedman JH, Rosenfeld M. GABAa versus GABAb Hypothesis of Catatonia: Reply to Letters to the Editor. Movement Disorders 1999;4:702-703
57. Friedman JH. Clozapine improved psychosis without worsening parkinsonism. Summary
published in: Evidence Based Mental Health 1999; 2 (4): 118 58. Friedman JH: Levodopa or Dopamine Agonist? (Commentary). Neurology Reviews 1999;
7:45-46 59. Tabamo REJ, Fernandez, HH, Friedman, JH, Lucas PR. Spinal Surgery for Severe Scoliosis
in Parkinson’s Disease. Medicine & Health Rhode Island 2000;83(4):114-115. 60. Friedman JH, Factor SA. Atypical Antipsychotics: Clozapine-Related Cardiac
Complications. Movement Disorders 2000 (Letters to the Editor) 15; (6): 1300 61. Friedman JH, Fernandez HH. Don’t Stop Stem-Cell Research. Commentary, The Providence
Journal Newspaper of Rhode Island. February 14, 2001 ppB-7. 62. Friedman JH. When profits beat ethics. Commentary, The Providence Journal Newspaper of
Rhode Island. March 9, 2001. 63. Friedman JH, Fernandez HH, Factor SA. TREATMENT OF PSYCHOSIS IN
PARKINSON’S DISEASE. (Letters to the Editor) The Journal of the American Medical Directors Association March/April 2001 Vol 2 Num 2 Pages 99-100.
64. Friedman, JH. Effects of Reviewing DATATOP Videotapes on IQ and MMPI in PSG
Coordinators and Investigators, or, Whatever Happened to Tony Lang? Movement Disorders 2001 16; (4) pp. 792
65. Friedman, JH. God bless rich women with mustaches. Commentary, The Providence
Journal Newspaper of Rhode Island. July 12, 2001. 66. ▼Friedman, JH. Why Parkinson’s Disease Patients Should Not Go To The Emergency
Room. The American Parkinson Disease Association, Inc., Newsletter, Educational Supplement #16. Published July 2001.
67. Friedman, JH. Breaking a Nurse’s Spellbinding diagnosis. Case analysis published in The
Cortland Forum. August 25, 2001 pp. 39-40 68. Friedman, JH. Battering Brains for Bucks. Commentary, The Providence Journal Newspaper
of Rhode Island. September 9, 2001. 69. ♣Friedman, JH. Fatigue in Parkinson’s disease. The American Parkinson Disease
Association, Inc., Newsletter. Fall 2001 Newsletter.
27
27
70. Friedman, JH. Episodic Camptocormia in PD. Movement Disorders 2001;16 (6):1201. (Letters to the Editor)
71. Friedman, JH. Why Parkinson’s Disease Patients Should Not Go To The Emergency Room.
Re-printed in the Italian Medical Journal “Novità AIP Annoix” – n.3 November 2001 72. Friedman, JH. Journal Watch Neurology 2002 4(6) 47. New Evidence for Genetic
Contribution to Parkinson's Disease. 73. Friedman, JH. American Parkinson's Disease Association Spring 2002 Newsletter. Medical
Update. "Research in Parkinson's Disease." April 2002. 74. Friedman, JH. NEUROLOGY IN PRIMARY CARE. 1999 Copyright © by Butterworth-
Heinemann 75. Friedman JH, Duffy J. Pre-Test Board Review Questions in Neurology and Psychiatry.
McGraw Hill, NY. Ibid. Edition 3. 1996. 76. Fatigue in Parkinson’s Disease. Re-printed in The Italian Parkinson’s disease Association
Newsletter. July 9, 2002. 77. Friedman JH. Hallucinations and Parkinson’s Disease. Printed in The American Parkinson
Disease Association, Inc. Summer 2002 Newsletter. Page 4. 78. Friedman JH. No autopsy, please: He’s suffered enough. Commentary, Printed in The
Providence Journal. August 4, 2002. 79. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson’s disease (letter). Mov
Disord 2002;17:221-222. 80. Friedman, JH. Klintenberg et al., Tardive dyskinesia Model in the Common Marmoset
(letter). Mov Disord 2002;18(1):114-115. 81. Friedman, JH. Reporting Enrollment in Clinical Trials: Comments & Responses. Ann of Int
Med 2002;37(12):1007(letter). 82. Friedman, JH. 18F-Dopa vs dopamine transporter ligands in positron emission tomographic
and single-photon emission computed tomographic scans for Parkinson’s disease. Arch Neurol. 2002;59(12):1973; author reply 1973-4
83. Friedman, JH. Placebo response. Lancet Neurology Network 2002;4(1):2. 84. Friedman, JH. Atypical antipsychotics in the EPS-vulnerable patient.
Psychoneuroendocrinology 2003;28 Suppl 1:39-51.
28
28
85. Friedman JH. Atypical Antipsychotics: Mechanism of Action. C J Psychiatry 2003;48:57-58(letter)
86. Friedman JH. Drug-induced Parkinsonism in Older Adults. Ger & Aging 2003;6(10):51-54 87. Friedman JH. Sleep and Parkinson’s disease. The American Parkinson Disease Association,
Inc., Newsletter, Fall 2003. 88. Appel J, Friedman JH. Genetic Markers and the Majority’s Right Not to Know. Mov Disord
2004;19(1)113-114(letter to the editor) 89. Friedman JH. Historical Perspective on Tardive Dyskinesia. J Clin Psychiatry. March 2004. 90. Friedman JH. Historical Perspective on Movement Disorders. J Clin Psychiatry
2004;65(supp 9). 91. Friedman JH. Ophthalmologic features of Parkinson’s disease. Neurology 2004;63(5):940-
941. (Letter to the Editor). 92. Friedman JH. More on Repetitive Behaviors in Parkinson’s Disease. Movement Disorders
2005;20(4):509. (Letter to the Editor). 93. Friedman JH. Fatigue in Parkinson’s Disease. APDA Educational Supplement 20, 2005. ▼Re-Printed in the Italian Medical Journal “Novità AIP Annoix” – n.3 November 2001 ♣ Re-printed in The Italian Parkinson’s disease Association Newsletter. July 9, 2002. CHAPTERS 1. Friedman JH: Drug Induced Parkinsonism. Lang AE, Weiner W (eds). Drug Induced
Movement Disorders. Futura Press, 1992 2. Friedman JH: Essential Tremor. R. Johnson and J. Griffin (eds). Current Therapy in
Neurologic Disease. 4th ed. Mosby-Year Book. l993:273-276. 3. Friedman JH: Post Encephalitic Parkinsonism. Chapter 14. In: Stern MB, Koller WC (eds).
Parkinsonian Syndromes, Neuroscience Series. Marcel Dekker, Inc. New York l993:203-226.
4. Friedman JH: Parkinson's disease and other akinetic rigid syndromes. Chapter in Feldmann
E (editor). Current Diagnosis in Neurology. Mosby-Year Book, Inc.1994:185-188. 5. Friedman JH: Neuroleptic Malignant Syndrome and Other Neuroleptic Toxicity. Feldman E
(Editor). Current Diagnosis in Neurology. Mosby-Year Book, Inc. 1994:382-384. 6. Friedman JH:. Neurology of the Elderly. Chapter in: Reichel. W. (ed.). Clinical Aspects of
Aging, 4th edition. Williams and Wilkins Press. l995:175-186.
29
29
7. Friedman JH: Management of Psychosis in Parkinson's Disease. Chapter in Koller WC, Paulson GW (eds). Therapy in Parkinson's Disease, 2nd edition. Marcel Dekker Press, New York, 1995:521-532.
8. Friedman JH: Neuroleptic Malignant Syndrome. Gilman S, Goldstein GW, Waxman SG
(eds). Neurobase. Arbor Publishing Group. (Computerized textbook). 9. Friedman JH: Drug Induced Parkinsonism. Neurobase. (Computerized textbook). 10. Friedman JH. Stereotypies. Neurobase. (Computerized textbook). 11. Friedman JH: Parkinson's Disease. Sage JI, Mark MH (eds.) Practical Neurology of the
Elderly. Parkinson’s Disease in the Elderly. Marcel Dekker Inc. New York, NY 1996:625-663.
12. Friedman JH. Vascular Disease of the Spinal Cord. In Samuels M, Feske S (ed). Office
Practice of Neurology. Churchill Livingstone. 1995:470-474. 13. Friedman JH. Mental Changes in Parkinson's Disease. In Samuels M, Feske S (eds). Office
Practice of Neurology. Churchill Livingstone. 1995:633-637. 14. Friedman JH: Acute Drug-Induced Movement Disorders. Chapter In: Gilman S, Goldstein
GW, Waxman SG (eds) Neurobase, Rochester, NY: Arbor Publishers. 15. Friedman JH. Supportive pharmacological treatments. In LeWitt PA (ed). Handbook of
Movement Disorders. Marcel Dekker. (In Press). 16. Rich S, Friedman JH. The Treatment of Psychosis in Parkinson's Disease. In Stoudemire A,
Fogel B (eds). Medical Psychiatric Progress Vol 3. American Psychiatric Press. 1995:151-182.
17. Friedman JH. Emotion, Mood and Thought. Chapter in Textbook of Clinical Neurology.
Goetz WC, Pappert EJ (eds) WB Saunders, 1997. 18. Friedman JH. Stereotypy and Catatonia. In, Jankovic J, Tolosa E (eds). Parkinson's Disease
and Movement Disorders, 3rd ed. Williams and Wilkings Press, Baltimore, MD. l997. 19. Friedman JH. Parkinson’s Disease. In, Gilchrist JM (ed). Prognosis in Neurology.
Butterworth Heinemann. 1998:129-134 20. Friedman JH. Prognosis of neuroleptic malignant syndrome. Gilchrist JM (ed). Prognosis in
Neurology. Butterworth Heinemann.1998:379-381. 21. Friedman JH. Neurology for the Primary Care Provider. Butterworth Heinemann, Woburn,
MA. 1999.
30
30
22. Friedman JH. Therapy of Parkinson’s Disease. In Rakel RE. (ed). Conn’s Current Therapy 2000. W.B. Saunders Co. Philadelphia, PA 2000:918-924.
23. Friedman JH, Meltzer HY. Atypical Antipsychotic Drugs in Parkinson’s Disease. Weiner W,
Factor SA (eds). Parkinson’s Disease in the New Millennium. Futura Press 2001. 24. Friedman JH. Behavioral Dysfunction in Parkinson’s disease. Pfeiffer RF, Bodis-Wollner I
(eds). Clinical Neurosciences. (In Press). 25. Fernandez HH, Friedman JH. Neuroacanthocytosis. Neurobase.1999 26. Friedman JH. Stereotypy and Catatonia. In, Jankovic J, Tolosa E (eds). Parkinson's Disease
and Movement Disorders, 4th ed. Lippincott, Williams and Wilkings Press, Philadelphia, PA. 2002.
27. Jeste D, Friedman JH. Psychiatry for Neurologists. Humana Press, Boston, MA. In Press.
28.Friedman JH, Fernandez HH. Neuroleptic Malignant Syndrome. In Sethi K (Ed). Drug Induced Movement Disorders;Marcel Dekker, Inc. NY, NY. 2004, pp 165-192.
29. Friedman JH. The Nocturnal Man Dementia of the Parkinsonian Type. Grossberg G (ed). Atypical Antipsychotic Medications in Dementia. AKH Inc. and McMahon Publishing Group, New York, August 2004:50-60.
30. Friedman JH, Garber CE. Fatigue: A Common Comorbidity in Parkinson’s Disease. Ebadi M and Pfeiffer R (ed). Parkinson’s Disease. CRC Press. 2004:209-216
31. Friedman JH, Fernandez HH. Drug-Induced Movement Disorders. In: LeDoux M (ed). Animal Models of Movement Disorders. Elsevier Inc. 2005:713-724
32. Marsh LM, Friedman JH. Psychiatric Aspects of Parkinson’s Disease. In (Jeste DV,
Friedman JH. Eds.) Psychiatry for Neurologists. Humana Press. In Press.
33. Friedman JH, Trieschmann Me, Fernandez HH. Drug-induced parkinsonism. Drug Induced Movement Disorders, 2nd edition. Factor SA, Weiner W (Eds) Blackwell Publishing. 2005:103-139
34. Fernandez HH, Friedman JH. Acute Parkinsonism. Movement Disorder Emergencies.
Diagnosis and Treatment. Frucht SJ, Fahn S (Eds.). Humana Press, Boston, MA. 2005:9-28.
35. Jeste DV, Friedman JH (eds).Psychiatry for Neurologists. Humana Press, Boston, MA
2005.
31
31
36. Marsh L, Friedman JH. Psychiatric Aspects of Parkinson’s disease. In (Jeste DV, Friedman JH (eds). Psychiatry for Neurologists. Humana Press, Boston, MA 2005: 163-176.
COMMENTARIES FOR MEDICINE AND HEALTH, RHODE ISLAND
(Joseph H. Friedman, MD- Editor in Chief) Friedman JH. The Talking Frog and the Neurologist. Commentary for Medicine and Health, Rhode Island. 1997;Volume 80; No. 5. Fernandez HH, Friedman JH. New Anti-Parkinsonian Drugs. Health and Medicine, Rhode Island 1998; 237-238. Friedman JH. Point of View: New York’s “Bell” Regulations Revisited, A Reminiscence: Teach one, Do One, See One. Medicine and Health, Rhode Island 1998;81(10):330 Friedman JH. Good Taste. 1998; 81. Friedman JH. Health Insurance-Funded Research. Medicine and Health, Rhode Island 1998;81(12):385. Friedman JH. Substance Abuse Treatment: A Time for a National Outcome Oriented Approach. 1999;82(3):78. Friedman JH. Cure after Cure after Cure. 1999;82(4):118. Friedman JH. Trojan Horse Advertising 1999;82(5):150. Friedman, JH. Active Controlled Versus Placebo Controlled Trials. 1999;82(6): 186. Friedman JH. Winning the Battle but Losing the War. Asthma. July 1999;82(7)230. Friedman JH. Medical Etiquette: Pro and Con. August 1999;82(8):278. Friedman JH. Arthritis and the Mission of Medicine & Health/Rhode Island. September 1999;(82):314 Friedman JH. Vital Signs Stable. October 1999;82(10):346. Friedman JH. Omerta. (Ethics in Medical Practice) November 1999;82(11):382. Friedman JH. Driving and the Physician. A (More) Modest Proposal. December 2000;82(12):426. Friedman JH. Specialists and the Current Medical “System.” January 2000;83(1):2.
32
32
Friedman JH. No Brainer. (Hazards of Boxing) February 2000;83(2):34. Friedman JH. Second Opinions. March 2000;83(3):70. Friedman JH. Cognitive Sinks: The Black Holes of Neuropsychology: A Brief Overview. First Annual April (Fool’s) Commentary. April 2000;83(4):98-99. Friedman JH. “There Is No Constitutional Right to Health Care.” May 2000;83:(5)130. Friedman JH. The Academic-Corporate Interface in Medicine. June 2000;83(6)166-167 Friedman JH. Peer Review: Phony Data, Shoddy Work or Revolutionary Results? “Truth Will Out” July 2000:83(7) Friedman JH. Evidence-Based Medicine & Medical Myths. Aug. 2000:83 (8) 234-235 Friedman JH. Who’s the Criminal? Sept. 2000:83 (9) 266 Friedman JH. Best Doctors. October 2000:83 (10) 294 Friedman JH. Medical Errors. November 2000:83 (11) 334 Friedman JH. Prison Clinical Trials. December 2000:83 (12) 7 Friedman JH. Better Than Medicine January 2001:84: (1) 2 Friedman JH. What is Reality? February 2001:84 (2) 34 Friedman JH. Ethics, Money & Negative Studies. March 2001;84 (3):74 Friedman JH. Buy This Book! April 2001’84 (4):106 Friedman JH. Evolving Medicine. May 2001;84 (5):146 Friedman JH. Spells. June 2001;84 (6) :186 Friedman JH. Thank God For Rich Women With Mustaches. July 2001; 84 (7) :222-223 Friedman JH. Quackery in the Incurable. August 2001; 84 (8): 254 Friedman JH. Silence is Golden. September 2001; 84 (9) :286 Friedman JH. Looking Good, Feeling Bad, The Marilyn Monroe Syndrome. October 2001; 84 (10):314-315.
33
33
Friedman JH. Putting On Shoes – Acts of Humility. November 2001;84(11):350. Friedman JH. Move Over Lance Armstrong. December 2001;84(12):386. Friedman JH. Demented Politicians. January 2002;85:(1)2. Friedman JH. On Being Told I’m Disgusting: The Hateful Family. February 2002;85:(2) Friedman JH. No autopsy – he’s suffered enough. March 2002;85:(3) 78. Friedman JH. An April fool’s Day Commentary, What a difference a scale makes! April 2002;85:(4) 114. Friedman JH. Really Dead. May 2002;85(5) 146. Friedman JH. Brain Cramps. June 2002;85: (6) 174. Friedman JH. Iatrogenesis Imperfecta. July 2002;85(7) 198 Friedman JH. Ego. August 2002;85(8) 234. Friedman JH. Needless Tests. September 2002;85(9):262. Friedman JH. Being Solicitous Or Getting Even? October 2002;85: (10) 298. Friedman JH. Boston Migraines. November 2002;85(11) 330. Friedman JH. Needless Tests. (CME ISSUE) December 2002;85(2) 358. Friedman JH. (CME ISSUE) “The Evil Among Us” or “The Buck Stops There.” January 2003;86(1):2. Friedman JH. First Do No Harm – Unless…February 2003;86(2):38 Friedman JH. On Choosing One’s Patients. March 2003;86(3):66 Friedman JH. Alien Abductions as a Risk Factor for Parkinson’s Disease [April Fool]. April 2003;86(4):0 Friedman JH. How Much Choice Does a Patient Have? May 2003;86(5):26 Friedman JH. We Can’t Afford To See Patients. (CME ISSUE) June 2003;86(6):58 Friedman JH. On Reviewing Manuscripts. (CME ISSUE) July 2003;86(7):190
34
34
ABSTRACTS 1. Friedman JH, Feinberg SS, Feldman RG: A neuroleptic malignant like syndrome due to
L-DOPA withdrawal. Presentation at the 109 meeting of the American Neurological Association, Baltimore, MD, October, 1984. Neurology
2. Rosen JM, Feinsilver SH, Friedman JH: Increased Carbon Dioxide Responsiveness in
Parkinson's Disease: Evidence for a Role of CNS Dopamine in Ventilatory Control. Presented at American Thoracic Society Annual Meeting, 1985.
3. Friedman JH, Rosen *JM, Feinsilver SH: Altered ventilatory control in Parkinson's
Disease. Presented at the International Symposium on Parkinson's Disease, 1985, New York.
4. Friedman JH, Giambalvo C: Effects of chloramphenicol on supersensitivity induced by
chronic administration of neuroleptics. Presented at the llth meeting of the American Neurological Association, Chicago, IL. October, 1985. Ann Neurol 1985;18:138.
5. Friedman JH, Hollmann PA: Acetazolamide responsive paroxysmal hereditary ataxia.
Presented at the 38th Annual Meeting of the American Academy of Neurology, New Orleans, April, 1986. Neurology 1986; 36(4):276.
6. Sabaawi M, Friedman JH, Wagner RL, Kucharski TL, Klein F: An objective measure of
akathisia. Presented at the Annual Meeting of the American Psychiatric Association, Washington, DC, May, 1986.
7. Kucharski TL, Wagner R, Friedman JH: An investigation of the coexistence of tardive
dyskinesias, parkinsonism and akathisia in chronic psychiatric patients. Present at the 26th Annual Meeting of the New Clinical Drug Evaluation Unit (NIMH). Key Biscayne, FL, May, 1986.
8. Rafal RD, Inhoff AW, Friedman JH, Bernstein E: Programming of sequential finger
movements in Parkinson's Disease. (Abstract) J Clin and Exp Neuropsych 1987;9(l):80. 9. Parkinson's Disease Study Group: Correlates of Clinical Decline in Early Parkinson's
Disease. Presented to the American Academy of Neurology, April. 1987 (Abstract). Neurology 1987;37(l):278.
10. Vesse L, Friedman JH, Giambalvo C: The effects of Chloramphenicol on the
Dopaminergic System of the Rate. Presented to the New England Pharmacology Association Providence, Rhode Island. January, 1988.
11. Friedman JH: An open label trial of Sinemet CR4 in mild to moderate Parkinson's
Disease. Presented at the AAN Meeting, April, 1988 Neurology 1988;38(l):180.
35
35
12. Friedman JH, Davies R, Wagner RL: Neuroleptic malignant syndrome: results of a six months prospective study at a state psychiatric hospital. Presented at the AAN Meeting, April, 1988. Neurology 1988;38(I):179.
13. Pollak J, Eslinger P, Friedman JH: Neurobehavioral study of dementia pugilistica.
Presented at the AAN Meeting, April, 1 1988. Neurology 1988;38(l):414. 14. Collyer CE, Friedman JH, Collyer RJ: Temporal measures of tapping by patients with
Parkinson's Disease. Presented to Eastern Psychological Association, April 1988. Proceedings and Abstracts of the Annual Meeting of the Eastern Psychological Association 1988;54:33.
15. Friedman JH, Lannon MC: Clozapine in the treatment of psychosis in Parkinson's
Disease patients. Presented at the American Academy of Neurology 4/89, Chicago. Neurology 1989;39(suppl.1):389.
16. Lewitt P, Friedman JH, Watts R, et al: Cortico-Basal Ganglionic Degeneration. Presented
at the American Academy of Neurology 4/89, Chicago. Neurology 1989;39(suppl. 1):140.
17. Belliveau J, Friedman JH: Cerebrospinal fluid copper levels in Parkinson's Disease.
Presented at the IV World Conference on Clinical Pharmacology and Therapeutics, July, 1989. (Abstract)
18. Friedman JH: Rubral Tremor Induced by Neuroleptic in a Patient with Cerebellar Ataxia.
First International Congress of Movement Disorders. Washington, DC. April, 1990. Movement Disorders Supplement 1990;5:47.
19. Friedman JH, Lannon MC: Clozapine responsive rest tremor in Parkinson's Disease.
Presented at the First International Congress of Movement Disorders. Washington, DC. April, 1990. Movement Disorders Supplement 1990;5:50.
20. Lannon MC, Friedman JH, McKnight P: Continuous enteral infusion of carbidopa/1-dopa
for control of clinical fluctuations in Parkinson's disease. Presented at the American Academy of Neurology, April 1991, Boston.
21. Lieberman P, Kako ET, Friedman J, Tajchman G, Feldman LS, Jiminez EB: Speech
production, syntax comprehension, and cognitive deficits in Parkinson's disease. Proceedings of 16th Annual Boston University Conference on Language Development p.21, Boston: Boston University
22. Karczmar P, Benditt JO, Friedman JH, McCool FD: Exercise Capacity in Parkinson's
Disease. Presented at the American Thoracic and Lung Society, 5/92. 23. Friedman JF, Caley C, Lannon M: Clozapine and Movement Disorders:A Retrospective
Analysis of 38 Patients. Ann Neurol 1992;32:277.
36
36
24. Friedman JH, Friedman H: Fatigue in Parkinson's Disease. Presented at American
Academy of Neurology Meeting, April l993. Neurology 1993;43 (Suppl):A237-238. 25. Krupp B, Friedman J, Cohen R. Anxiety in Parkinson's Disease. Am Psych Assoc. l993.
San Francisco, CA. 26. Hubble J, Friedman J. Pramipexole (SND 919). Presented at the World Congress of
Neurology 9/93. 27. Wilterdink J, Friedman JH. Simultaneous Homologous Movements in Asymmetric
Parkinson's Disease. Ann Neurol l993;304:302. 28. Friedman JH, Wilterdink J, Sanes J. Changes in tone with reinforcement maneuvers in
asymmetric Parkinson's disease. Ann Neurol l993;34:266. 29. Lieberman P, Friedman JH. Speech Motor and Cognitive Deficits in Parkinson's Disease.
Presented at the International Symposium on Dementia in Parkinson's Disease, Jerusalem, Israel. 3/94. Behav Neurol l994;7:20.
30. Gordon N, Friedman JH, Rich S. ECT in Parkinson's Disease. Presented at the
International Symposium on Parkinson's Disease. Behav. Neurol 4/94. 31. Mark M, Dickson, DW, Sage J, Schwarz KO, Walters A, Lazzarini A, Duvoisin R, Miller
D, Gordon M, Friedman J, Goldman J. Familial Lewy Body Disease. Neurology 1994;44(4):A248.
32. Trosch RM, Friedman JH, LeWitt PA. Clozapine Treatment of Dystonia in Parkinson's
Disease. Movement Disorders l994; 9(Suppl 1):102. 33. Galvez-Jimenez N, Friedman J, Lang AE. A Consistent Pattern in Three Cases of Senile
Chorea. Neurology l995;45(4):A185. 34. *Friedman JH, Epstein M, Sanes J, Daamen M, Lieberman P, Cullen K, Lindquist C.
Gamma Knife Pallidotomy in Advanced Parkinson's Disease. Presented at the 120th Meeting of the ANA. Ann Neurology l995;38:329
35. Friedman JH, Koller WC, Lannon MC, et al: BCLOZ: A Double blind crossover trial
comparing clozapine and benztropine for the treatment of tremor in Parkinson's disease. Presented at AAN annual meeting, San Francisco, CA. March, l996.
36. Lieberman A, et al. Pramipexole in Parkinson's disease. Presented at the meeting of the
American Academy of Neurology in San Francisco, CA. March, l996. 37. Trosch RM, West Bloomfield MI, et al. Clozapine Use in Parkinson's Disease. Part of
the Clozapine Collabortive Group. Neurology l996;46(suppl): A375-376. March, l996.
37
37
38. Friehs GM, et al. Putaminal Infarct after Unilateral Gamma Knife Pallidotomy for
Parkinsonism. 8th International Leksell Gamma Knife Society Meeting: Marseille, France June 22-25, 1997.
39. Panisset M, Siderowf A, McDermott M, Kieburtz K, Friedman JH, Growdon J and the
Parkinson’s Study Group: Baseline Predictors of Subsequent Dementia in the DATATOP Cohort. Presented at the PSG/MDS 11th Annual Symposium. September 28, 1997.
40. Marek K, Friedman J, Hauser R, Juncos J, LeWitt P, Miyawaki E, Tarsy D, Olanow CW,
Stern M, Levy R, Mulcahy: Phase II Evaluation of Rasagiline Mesylate (TVP-1012), a Novel Anti-Parkinsonian Drug, in Parkinsonian Patients Not Using Levodopa/Carbidopa. Presented at the PSG/MDS 11th Annual Symposium. September 28, 1997.
41. Friedman JH, Goldstein S, Jacques C. Substituting Olanzapine for Clozapine in
Parkinson’s disease patients with drug-induced results of an open-label prospective study of psychosis. Presented at the 4th Congress of the European Society for Clinical Neuropharmacology. December 4, 1997
42. Friedman JH, Goldstein S. Olanzapine in the Treatment of Psychosis in Parkinsonian
Patients. Poster presented at the 4th Congress of the European Society for Clinical Neuropharmacology. December 1997
43. Rosenfeld M, Friedman JH, Jacques C. Quetiapine Pilot Trial in Dopamimetic Psychosis
(DP) in Parkinson’s Disease (PD). Presented at the 5th International Congress of Parkinson’s Disease and Movement Disorders. October 10-14, 1998.
44. Friedman JH, Fernandez HH, Krupp B. Punding on L-Dopa. Presented at the 5th
International Congress of Parkinson’s Disease and Movement Disorders. October 10-14, 1998.
45. Fernandez HH, Friedman JH, Rosenfeld M, C. Quetiapine for the Treatment of Drug-
Induced Psychosis in Parkinson’s Disease. Presented at the American Academy for Geriatric Psychiatry; 1999; 14-17.
46. Neill M, Friedman JH, Crausman R, Schwartz S, Talkington D. Persistent
Hypolglycorrhacia in CNS Infection with Mycoplasma pneumoniae. Clin Infect Dis 1998;27:1019
47. Fernandez HH, Friedman JH, Krupp B. The Course of Tardive Dyskinesia in Psychiatric
Patients: A 14-Year Follow-up Study. Presented at American Academy of Neurology 51st Annual Meeting. Toronto Canada. April 17-24, 1999.
38
38
48. Friedman JH, Fernandez HH, Jacques CJ, Rosenfeld M. Quetiapine for the Treatment of Drug-Induced Psychosis in Parkinson’s Disease. Poster presented at the American Academy of Neurology 51st Annual Meeting. Toronto, Canada. April 17-24, 1999.
49. Friedman JH, Fernandez HH, Jacques CJ. Quetiapine Fumate for the Treatment of
Dopamimetic Psychosis in Parkinson’s Disease. Abstract presented at the American Psychiatric Association Annual Meeting. Washington, DC. May 15-20,1999.
50. Fernandez HH, Lapane K, Friedman JH. Gender Differences in the Prevalence and
Treatment of Behavior Problems in Parkinson’s Disease. Parkinsonism and Related Disorders 1999; 5:S89.
51. Lapane K, Fernandez H, Friedman JH. Pharmacologic Treatment of People with
Parkinson’s Disease Living in Long-term Care. 15th International Conference on Pharmacoepidemiology, Boston, MA. August 26-29 1999
52. Fernandez HH, Famiglietti EV, Friedman JH. Probable Cornelia De Lange Syndrome
with Progressive Parkinsonism and Dystonia. Movement Disorders 1999; 14:907. 53. Fernandez HH, Friedman JH, Lannon MC. Clozapine Replacement by Quetiapine for
Dopamimetic Psychosis in Parkinson’s Disease. 124th Annual Meeting of the American Neurological Association (ANA), October 13, 1999, Seattle, WA.
54. Fernandez HH, Friedman JH, Jacques C. Quetiapine for the Treatment of Drug-Induced
Dopaminetic Psychosis in Parkinson’s Disease. 1999 APA Institute of Psychiatry Services, Annual Meeting, October 31, 1999, New Orleans, LA.
55. Fernandez HH, Lapane KM, Friedman, JH. Gender Differences in the Prevalence and
Treatment of Behavior Problems in Parkinson’s Disease. Parkinsonism & Related Disorders 1999; 5:S89 Abstracts of the XIII International Congress of Parkinson’s Disease July 24-28 1999 – Vancover, Canada
56. Friedman JH, Fernandez HH, Jacques C, Goldstien JM. Quetiapine for the Treatment of
Dopaminetic Psychosis in Parkinson’s Disease. Annual Meeting of the American College of Neuropsychopharmacology.
57. Primary Progressive Freezing Gait Disorder (PPFG): A Neuroimaging Study to Evaluate
Dopamine Transporter Density. American Academy of Neurology 52nd Annual Meeting. April 29-May 6 2000 San Diego, California.
58. Primary Progressive Freezing Gait Disorder (PPFG): A Clinical Study with Evaluation of
the Natural History in 29 Patients. American Academy of Neurology 52nd Annual Meeting. April 29-May 6 2000 San Diego, California.
39
39
59. T. Zawacki, J. Grace, J. Friedman, L. Sudarsky. Impaired Executive Abilities in Six Patients with Machado-Joseph Disease. International neuropsychological Society, February 2001, Chicago, IL. Journal of the International Neuropsychological Society
60. J.H. Friedman and H. Friedman Long Term Follow-up of Fatigue in Parkinson’s Disease.
Abstract Presented at the American Neurologic Association; Fourteenth Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders, Boston, Massachusetts October 2000
61. H.H. Fernandez, J.H. Friedman, A.J. Fischman, R.B. Noto. Is Altropane SPECT More
Sensitive than Fluro DOPA PET in Detecting Early PD? Abstract Presented at the American Neurologic Association; Fourteenth Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders, Boston, Massachusetts October 2000
62. CE Garber, FACSM SL Rourke, Chlouba, S. Courtright, M. Malhortra, & J. H.
Friedman. Functional Ability And Functional Capacity In Patients With Parkinson’s Disease. Abstract Presented at the American College of Sports Medicine annual meeting 2001, Baltimore, MD, June 2001
63. Zawacki, T., Grace, J., Friedman, J.H., Sudarsky, L. Impaired Executive Abilities in Six
Patients with Machado-Joseph Disease. Presented at the International Neuropsychological Society, Chicago, IL. February 2001
64. Zawacki, T., Grace, J., Friedman, J.H., Sudarsky, L. Impaired Executive Abilities in Six
Patients with Machado-Joseph Disease. Presented at the Annual Research Meeting of the Department of Psychiatry and Neuroscience’s at Brown University Training Consortium. Providence, Rhode Island. January 2001
65. Fernandez, HH, Trieschmann, ME, Burke, MA, Jacques, C, Friedman, JH. The Long-
Term Effect of Quetiapine on Drug-Induced Psychosis among Parkinsonian patients. Presented at the XIV International Congress on Parkinson’s Disease. July 27-August 1 2001, Helsinki, Finland.
66. Friedman, JH et al. Fifteenth Annual Symposia on Etiology, Pathogenesis And Treatment
Of Parkinson’s Disease And Other Movement Disorders. Co-Sponsored by the Parkinson Study Group, Under the Auspices of the American Neurological Association’s 126th Annual Meeting. “A Multi-Center, Randomized, Double-Blind Pilot Study comparing TV-1203 and Levodopa Tablets in Advanced Parkinson’s Disease Patients with Response Fluctuations. (Abstract) September 30th 2001. Chicago, IL.
67. Friedman, JH et al. Fifteenth Annual Symposia on Etiology, Pathogenesis And Treatment
Of Parkinson’s Disease And Other Movement Disorders. Co-Sponsored by the Parkinson Study Group, Under the Auspices of the American Neurological Association’s 126th Annual Meeting. “Drug-Induced Psychosis in Parkinsonian Syndromes: Predictors of Quetiapine Non-Response. (Abstract) September 30th 2001. Chicago, IL.
40
40
68. Fernandez, HH; Trieschmann, ME; Burke, MA; Jacques, C and Friedman, JH. First
International Symposium on Mental & Behavioral Dysfunction in Movement Disorders. Montreal, Canada. October 10-13 2001. Long-Term Outcome of Quetiapine Use For Psychosis: Parkinson’s Disease Versus Dementia With Lewy Bodies. Movement Disorders vol 16/suppl 1 2001.
69. Fernandez, HH, Trieschmann, MA Burke, C, Jaques, C. and Friedman, JH. Drug-
Induced Psychosis in Parkinsonian Syndromes: Predictors of Quetiapine Non-Response. (Poster) Movement Disorders, Vol. 16, No. 5, 2001. Presented by JH Friedman at the Fifteenth Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson’s Disease and Other Movement Disorders. September 30, 2001. Chicago, Illinois.
70. Fernandez, HH, Trieschmann, MD, Burke, MA, Jacques, Friedman, JH. Long-term
Outcome of Quetiapine for Psychosis Among Parkinsonian Patients. Abstracts From the AAGP 15th Annual Meeting: Feb 24-27, 2002, Orlando, Florida. Printed in The American Journal of Geriatric Psychiatry Pg 98 Vol 10(2) Sup 1 March –April 2002
71. Scoggan, KA, McRory, JE, Santi, CM, Snutch, TP, Friedman, JH, Bulman, DE. A novel
CACNA1A missense mutation in a family with EA-2 results in complete loss of P/Q-type calcium channel function. Am J Hum Genet. 71:A549.
72. Friedman JH, Messing S, Oakes D, et al. A Descriptive and Comparative Analysis of
Psychotic Symptoms in Three Placebo-Controlled, Double-Blinded Trials of Atypical Antipsychotic Drugs in the Treatment of Drug-Induced Psychosis in Parkinson’s Disease. Movement Disorders 2002;17:1105
73. Truong D, Friedman, JH et al. Acute Effects of Neotrofin in Patients with Parkinson’s
Disease. Movement Disorders 2002;17:1106. 74. Factor SA, Friedman JH, and the Parkinson’s Study Group. Longitudinal Outcome of
Parkinson’s Disease Patients with Psychosis: Persistence of Behavioral Impairments, Mortality and Nursing Home Placement. Movement Disorders 2002;17:1105-1106.
75. Friedman, JH, Jennings D, Marek K, Seibyl J. β-CIT SPECT Imaging to Distinguish
Drug-Induced Parkinsonism from Idiopathic Parkinson’s Disease Exacerbated by Drugs: Pilot Data. Part I. Mov Dis 2002;17:1108
76. Skeete R, Friedman JH, Fernandez HH. Under-recognition of parkinsonism in a
community teaching hospital. Movement Disorders 2002; 17 (5): 1112. Also presented at the 16th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson’s Disease and Other Movement Disorders. New York, NY, October 2002.
77. Fernandez HH, Friedman, JH, Factor SA, Molho E, Coskun JD and Lansang MC, New
onset diabetes among parkinsonian patients on long-term clozapine use. 7th International
41
41
Congress for Parkinson’s Disease and Movement Disorders. Miami, Fl, November 11, 2002.
78. Fernandez HH, Donnelly EM, Friedman JH. Long-Term Outcome of Clozapine Use for
Psychosis Among Parkinsonian Patients. Presented at the 7th International Congress for Parkinson’s Disease and Movement Disorders. Miami, Fl, November 13, 2002.
79. GPI 1485 Trial Group. A 2 Year Randomized, Placebo Controlled Trial of the
Neuroimmunophilin Ligand, GPI 1485 on Dopamine Transporter Density and Parkinson’s Disease Progression: Design and Patient Baseline Characteristics. Presented at the International Parkinson’s Disease Symposium, Rome, Italy, June 2004.
80. Borek L, Kohn R, Friedman JH. Mood and Sleep in Parkinson’s Disease. Presented at the
9th Annual Research Symposium on Mental Health Sciences, Brown University (2nd prize), March 2005 and the American Psychiatric Association Meeting, May 2005.
81. Gharabawi GM, Greenspan A, Friedman J. Clearing the confusion in identification,
classification and management of drug-induced movement disorders: An interactive trial. Intl Coll Neuropsychopharmacology. Nov 2005.
82. Schifitto G, Friedman JH, Oakes D, et al. Fatigue in levodopa-naïve subjects with early PD. Mov Disord 2006;21(suppl 13).S91
83. Borek LL, Kohn R, Friedman JH. The phenomenology of dreams in Parkinson’s disease. Mov Disord 2006;21 (suppl 13).S97
84. Moro-de-Castillas, Jacques C, et al. REM sleep behavior disorder and testosterone levels in men with Parkinson’s disease. Mov Disord 2006;21(suppl 13).S98
85. Mendelsohn A, Friedman JH, Grace J. A comparison of fatigue measures in Parkinson’s disease. Mov Disord 2006;21(suppl 13).S98
86. Chou KL, Piccirillo ML, Smith M, Friedman JH. Delayed auditory feedback in Parkinson’s disease (PD) patients with festinating speech. Mov Disord 2006;21(suppl 13):S128.
INVITED PRESENTATIONS (THREE YEARS) “Neurological Update 2002” Sponsored by the Department of Neurology University of Miami School of Medicine. Drug Induced Movement Disorders. February 1, 2002. Miami Florida. Brockton Veterans Administration. Medical Grand Rounds. Atypical Antipsychotic drugs in Patients with Movement Disorders. February 7, 2002. Brockton, MA. “Practicum in Neurology-Controversies & Clinical Pearls”. Management of non-motor signs and symptoms in Parkinson’s disease, University of Toronto. February 8,2002, Key Largo, Florida.
42
42
Medical Grand Rounds. “Update in Parkinson’s Disease.” February 20, 2002. Memorial Hospital of Rhode Island. Pawtucket, RI. Medical Grand Rounds. “The Role of Atypical antipsychotics in Patients Presenting with Movement Disorders.” March 7, 2002. Edith Rogers Memorial Veterans Administration Hospital. Bedford, MA. Neurology Grand Rounds. “Drug Induced Psychosis in Parkinson’s Disease.” March 14, 2002. The University of California at San Diego. San Diego, CA. Psychiatry Grand Rounds. “Atypical Antipsychotics in Movement Disorders & Extrapyramidal Symptoms Relating to Atypical Antipsychotics.” April 4, 2002. Arbor Hospital, Jamaica Plain, MA. 54th American Academy of Neurology Annual Meeting, Denver, CO. "Atypical Antipsychotics and Treatment of Psychosis in Parkinson's disease." April 19, 2002. Dartmouth-Hitchcock Medical Center Neurology/Neurosurgery Grand Rounds. "The Risks Associated with the use of Antipsychotics in the Elderly." Hanover, New Hampshire. May 3, 2002 Geriatric Psychiatry Case Conference and Journal Club. Butler Hospital, Providence, RI. "Motor Side Effects of Atypical Antipsychotics in Vulnerable Populations." May 9, 2002. Morton Hospital & Medical Center, Neurology Grand Rounds sponsored by Elder Behavioral Health Services. The Risks Associated with the use of Antipsychotics In the Elderly. August 14, 2002. Taunton, MA. The 4th Biennial Symposium on Parkinson’s Disease: Behavioral Aspects of Parkinson’s Disease. Clarion Hotel, South Burlington, VT. September 13, 2002. Albany Medical Center, Neurology Grand Rounds. Early treatment options in Parkinson’s disease. Albany, NY. September 26, 2002. Invited faculty member to teach course (Clinical Neurology for Psychiatrists) sponsored by Montefiore Medical Center, Credit issued by Albert Einstein College of Medicine. “Drug Induced Movement Disorders.” New York City, NY. October 4, 2002 American Psychiatric Association 54th Annual Symposium on Psychiatric Services. Critical Issues in the Optimal Use of Atypical Antipsychotics in Treating Schizophrenia: Antipsychotics in Patients with Movement Disorders. Chicago, IL. October 10, 2002. Movement Disorders Society’s 7th International Congress of Parkinson’s Disease and Movement Disorders. Management of levodopa-induced hallucinations/behavioral disturbance. November 11, 2002. Miami, FL.
43
43
University of Pennsylvania School of Medicine Symposium on Mind and Brain. Drug-induced psychosis in Parkinson’s disease: Clinical features and management. November 22, 2002. Philadelphia, PA New Hampshire State Hospital, Neurology Grand Rounds. EPS and movement disorders and their relationship to atypical antipsychotics. December 19, 2002. Concord, NH. The Mental Health Center of Greater New Hampshire. Neurological complications associated with the use of antipsychotics. December 19, 2002. Manchester, NH. AstraZeneca CNS Advisory Board Meeting, Psychoses and Parkinson’s Disease, February 2, 2003, Scottsdale, AZ Neurology Grand Rounds, U of Kansas, Kansas City, Ka. Drug Induced Psychosis in Parkinson’s Disease. March 14, 2003, Kansas City, KA Our Lady of Fatima/St Joseph’s Hospital. Geriatric Psychiatry In Service on The risks associated with the use of atypical antipsychotics in the elderly. North Providence, RI March 19, 2003. AstraZeneca, Educational talk for nurse practitioners, psychiatrists and social workers, Drug Induced Psychosis in Parkinson’s Disease, May 2, 2003, Framingham, MA AstraZeneca Medical Education Program, Antipsychotics in the Elderly: Therapeutic Considerations, May 6, 2003, Chattanooga, TN AstraZeneca Medical Education Program, Antipsychotic Use in Special Populations, May 22, 2003. Plymouth, MA Rhode Island Hospital, Providence, RI, Fundamentals of Geriatrics Conference, Fall, July 24, 2003 Fairview Developmental Center, Costa Mesa, CA. Drug induced movement disorders. Sept 9, 2003 Long Beach Veteran’s Administration Hospital. Atypical antipsychotics in vulnerable populations. Sept 10,2003, Long Beach, CA Robert F. Kennedy Hospital. Hawthorne, Ca. Atypical antipsychotics in vulnerable populations. Sept 11, 2003 New England Geriatrics nursing association. Dementia with Lewy Bodies. 8th Intl Symposium on the Treatment of Parkinson’s Disease, Sleep Disorders in PD and Their Treatment, Kobe, Japan. Sept 27,28. Reading Hospital, Reading, Pa. Sleep and fatigue in PD; Non motor problems of PD
44
44
Psychiatry Grand Rounds . Nov 11, 2003 Allentown State Hospital, Allentown, Pa: Atypical antipsychotic and Parkinson vulnerable populations. November 12, 2003 Wernersville State Hospital, Wernersville, PA: Atypical antipsychotics and Parkinson vulnerable populations. November 12, 2003 St. Elizabeth’s Hospital, Brighton, MA :“Neurological Complications Associated with the Use of Atypical Antipsychotics,” November 19, 2003 RI Chapter of Medical Directors Association, Update on the Diagnosis and Pharmacologic Approaches for the treatment of Parkinson’s Disease, November 20, 2003, Providence, RI University of Rhode Island, Lecture “Pharmacotherapy of Parkinsonism and Select Movement Disorders, December 1, 2003, Kingston, RI NINDS, Depression n Parkinson’s Disease: Diagnostic Issues, December 4-5, 2003, Washington, DC Butler Hospital, Geriatric Psychiatric Case Conference and Journal Club, Sleep and Fatigue in Parkinson’s Disease, January 8, 2004, Providence, RI ACADIA ACP-103 Investigator Meeting, Overview of PD Psychosis, Protocol Overview, January 10, 2004, Peachtree City, GA Spark Advisory Board Meeting Sponsored by Astra/Zeneca, Psychosis in Parkinson’s Disease, January 12, 2004, Toronto, ON, CA St. Luke’s Hospital, New Bedford, MA, Medical Grand Rounds. Antipsychotics in Parkinson Vulnerable Patients, February 3, 2004 Massachusetts Association of Physician Assistants, Burlington, MA. CME Conference, Drug Induced Movement Disorders, February 28, 2004 The Kent Center, Warwick, RI, Medical Grand Rounds. Atypical antipsychotics & Parkison’s. Movement Disorders? May 17, 2004 2nd Annual PADRECC/MIRECC (Univ of Penn) Symposium on Neurodegenerative Diseases: the Interface of Psychiatry and Neurology, Philadelphia, PA (CME certified course). Psychosis in Parkinson’s Disease. May 24, 2004 Memphis Mental Health Institute. Atypical Antipsychotic Drugs in Vulnerable Populations. June 10, 2004
45
45
University of Tennessee, Memphis, Neurology Grand Rounds. Drug Induced Psychosis in Parkinson’s Disease. June 11, 2004 University of Tennessee, Memphis, Psychiatry Grand Rounds. Drug Induced Psychosis in Parkinson’s Disease. June 11, 2004 National Assoc Directors of Nursing Administration/Long Term Care. Simple Steps: Assessing Psychotic symptoms and Abnormal Movements in the Elderly. June 16, 2004 CNS Divisional Meeting, Janssen Pharmaceuticals, Trenton, NJ. Drug Induced Movement Disorders. June 17, 2004 Bournewood Health Systems, Brookline, MA, Grand Rounds. Atypical Antipsychotics and Movement Disorders. September 20, 2004 Arbour Health System, Attleboro, MA, Academic Conference. Neurobiology. September 22, 2004 New England Biennial Conference (New England Regional APDA Meeting). Keynote Adress: Research Advances in PD. Oct 12, 2004. Annual Fall CME Conference, Focus on Primary Care (Massachusetts Association of Physician Assistants). Gait Abnormalities. October 13, 2004. MetroWest Medical Center, Natick, MA, Psychiatry Department Conference. EPS & antipsychotic drugs. October 26, 2004 Rhode Island Academy of Family Physicians Annual Conference in Newport, Rhode Island. Diagnosis and Treatment of Parkinson’s Disease. April 15, 2005 Organizer and Chair: Kinetics Foundation Conference on Fatigue in Parkinson’s Disease. May 2, 2005. Palo Alto, Ca Strategies for Late Stage Parkinson’s Disease. U.S. Army Neurotoxin Exposure Treatment Research Program; Bethesda, MD. July 20,2005. Symposium member and lecturer on Psychosis in PD. 9th Annual Northeastern Psychiatric Pharmacotherapy Symposium, Univ. of Connecticut School of Phamacy, Northampton, MA Sept 10,2005. Movement disorder side effects of antipsychotic drugs. Mass. Assoc of Physician Assistants (MAPA) annual meeting, Hyannis, MA Oct 05; Tremors Medical Grand Rounds, St Luke’s Hospital, New Bedford, MA. Atypical antipsychotics and the black box warning. Nov 1,20005
46
46
NINDS, Bethesda, Md. Parkinson’s disease psychosis. Presentation on phenomenology. 11/7/05 Psychiatry rounds. Carney Hospital, Dorchester Center, MA. Nov 16. Movement disorders and atypical antipsychotic drugs. Medical grand rounds. Kent County Hospital. Parkinson’s disease update. Nov 18, 2005 Geriatrics Society of America. Atypical Antipsychotic drugs and EPS in the elderly. Invited speaker. Orlando, FL Nov 21, 2005 Neurology grand rounds. Univ of Florida, Gainesville. Fatigue in Parkinson’s disease. Dec 6, 2005 Johnston-Northern Rhode Island Mental Health Center: Atypical antipsychotics and movement disorders. Dec 15, 05. Woonsocket, R.I. Arbour Psychiatric Clinic: Akathisia and other extrapyramidal side effects of antipsychotic drugs. Dec 21, 05. Brookline, MA International Society for CNS Clinical Trials Methodology. Behavioral aspects of Parkinson’s disease: challenges and opportunities. Feb 06. Washington, DC World Parkinson’s Disease Congress. Waxhington, DC. Feb 06. Psychosis in Parkinson’s disease. Catawba Mental Health Clinic, Rock Hill, S Carolina. Jan 06. Drug induced movement disorders Guilford Mental Health Center, High Point, NC Jan 06. Drug induced movement disorders Highpoint Regional Medical Center, High Point, NC Jan 06. Drug induced movement disorders. Broughton Hospital, Morganton, NC. Jan 06 Drug induced movement disorders FUNDING Bromocriptine, Phase IV Trial, Sandoz Corporation, 1986-1991, $14,280. J. Friedman, MD PI Sinemet CR, Phase III Trial, Merck, Sharpe & Dohme, Corporation 1986-1987. $46,000. J. Friedman, MD PI Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism. NIH Grant #lR0lNS24778-01, 1987-1992, $305,000. J. Friedman, MD PI at Brown. Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism-Extension-Somerset Pharmaceuticals $16,000. J. Friedman, MD PI. 1991-1992. Speech and Language in Parkinson's Disease: BRSG, Department of Linguistics, Brown University (with Philip Lieberman, Ph.D.) $5,000, 1987-Present. J. Friedman, MD Co-PI. SND-919. Boehringer Ingelheim, Inc. Phase 1 Trial of a new dopamine agonist. $196,368. J. Friedman, MD PI at Brown. 1991-1992. Clinical Director, Parkinson's Disease Referral and Information Center $25,000 per year. 4/91-Present. American Parkinson's Disease Association.
47
47
The safety, tolerance and influence on clinical status of RO-196327 in untreated Parkinson's disease patients (START-UP). Parkinson's Study Group. J. Friedman, MD PI at Brown University. $49,992. 1990-1992. The safety, tolerance and influence on clinical status of RO-196327 in levodopa exposed Parkinson's disease patients (STARTLE). Parkinson's Study Group. J. Friedman, MD PI at Brown University. $49,992. 1991-1992. Neural Control of Human Voluntary Movements. NIH. 1ROI NS28526- OlAl. Jerome Sanes, Ph.D. PI, J. Friedman, MD Subcontractor at Brown University. $10,000. 1991-Present. SND 919, Boehringer Ingelheim, Inc. Phase III trial of a new dopamine agonist, $146,000. J. Friedman, MD PI at Brown 1991-1992. Double-blind, Placebo-controlled, Parallel-group comparison to Assess the Safety, Tolerance, and Efficacy of Pramipexole in Early Parkinson's disease (Part I) and to Assess Long Term Safety with Open-Label Pramipexole (Part II). The UpJohn Company. PI Joseph H. Friedman, MD Part I $80,000. Part II $70,000. Total $150,000. 1993-1997. Double-Blind, Placebo-controlled, Parallel-group Comparison to Assess the Safety, Tolerance and Efficacy of Pramipexole in Advanced Parkinson's Disease (Study 0679) and to Assess Long-term Safety with Open-Label Pramipexole (study 0979). PI. Joseph H. Friedman, MD Boehringer-Ingleheim Pharmaceuticals #0679-$82,200. #0979-$80,972. Total $163,172. 1993-1997. A Randomized, Double-masked, vehicle-controlled Evaluation of the Safety and Efficacy of Intramuscular Botulinum Toxin Type A for the treatment of Essential tremor (ocul-144-8051). PI. Joseph H. Friedman, MD $107,500. 1993-1995. An Evaluation of Intramuscular Botulinum Toxin Type A (OculinumR) for the Treatment of Essential Tremor. PI Joseph H. Friedman, MD. $53,750. 1993-1994. Blinded Withdrawal of Deprenyl in DATATOP extension protocol (BLIND-DATE). PI. Joseph H. Friedman, MD $57,960. 1993-1995. A Phase III Multicenter Study to Evaluate the Efficacy and Safety of Entacapone, compared to placebo, in the treatment of Parkinson's Disease with Motor Fluctuations (SEESAW) PI. Joseph H. Friedman, MD $46,450. 1994-1996. Psychosis and Clozapine in Parkinson's Disease (PSYCLOPS)-Food and Drug Administration. PI. Joseph H. Friedman, MD. $300,000. Tolerability of TVP-1012 (PAI), A Novel MAO-B Inhibitor, in Parkinsonian Patients. Lemmon/Teva Pharmaceutical Industries Ltd. PI. Joseph Friedman, MD $43,600. January, l995 to 1996.
48
48
Cabergoline in the Treatment of Parkinson's Disease: A Placebo-Controlled Trial. Pharmacia, Inc. PI. Joseph Friedman, MD $64,254 Core; $28,254 Extension. March, l995 to 1997. A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study for the Safety, Tolerability, and Efficacy of Daily, Oral Doses of Remacemide Hydrochloride in Parkinson’s Disease Subjects with Motor Fluctuations (REAL) (Protocol #136) Astra Merck. $82,000 1997-1998 Noncomparative, Open-Label Study to Identify TASMAR Dosage Regimen in Nonfluctuating Parkinson’s Disease Patients Treated with Sinemet, with follow-up extension of TASMAR.l (Protocol #NR15440/M35016) Hoffman-LaRoche, Inc. $24,2111 1996-1998. Open-Label Study to Identify Reasons for TASMAR Dosage Regimen Changes in Fluctuating Parkinson’s Disease Patients, With a Follow-up Extension (Protocol #NR15441/M35019) Hoffman-LaRoche, Inc. $4,000 1997-1998. Olanzapine vs. Placebo for Treatment-Associated Psychosis in Patients with Parkinson’s Disease (Protocol #F1D-MC-HGFV). Eli Lilly and Company.1997-1998 A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study for the Safety, Tolerability, and Efficacy of SIB-1508Y in Parkinson’s Disease Patients who are Requiring but not Receiving Dopaminergic Therapy. (TEST-PD) (Protocol #SIB-1508Y-201) Sibia Neurosciences.$98,628 - 1997-1999 Earlier vs. Later L-Dopa in Parkinson’s Disease (ELLDOPA) NIH-1RO1 NS34796-01. $59,000. 1998-2001. PI: Fahn A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID for Two Years on the Progression of Parkinson’s Disease in 1050 Patients. RhÔne-Poulenc Rorer $69,525 1998-2001. PI: Friedman Parkinson is Research: The Organized Genetics Initiative (PROGENI) NIH RO1 N537167-01. Examine genetic and other risk factors, which may be important in the development of Parkinson’s disease. 9/1/1998-8/31/2004
Evaluation of the Safety and Efficacy of [123 ] - Altropane for the Detection of Parkinsonian Syndrome in Patients with Movement Disorders. Boston Life Sciences, Inc. 1998-1999 The Effects of Pramipexole on Depressive Symptoms in Parkinson’s Disease Patients. Joseph H. Friedman, Principal Investigator, Pharmacia & Upjohn ($24,000) 1999-2000 A Phase III Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study of the Effect of Riluzole 50mg BID or 100mg BID on the Progression of Parkinson’s Disease in patients treated with L-Dopa or Dopamine Agonist. RhÔne-Poulenc Rorer $84,896 1999-2003. PI: Friedman
49
49
Evaluation of the Safety and Efficacy of [123]-Altropane for the Detection of Parkinsonian Syndromes in Patients with Movement Disorders. (Boston Life Sciences, Inc.) 1999-2000 Pilot Huntington At Risk Observational Study (PHAROS). (Huntington Study Group). A prospective, multi-center, double-blinded observational study to determine the rate of illness onset (phenoconversion) in a cohort of individuals who are at immediate risk for inhteriting the HD gene. 1999-2007. PI: Shoulson A MultiCenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Escalating Transdermal Doses of SPM 962 in Subjects with Early Parkinson’s Disease. (Schwarz-Pharma). 1999-2000 A Multicenter, Double-Blind, Placebo-Controlled Study of the Tolerability and Effect of Entacapone in Parkinson’s Subjects With End-of dose Wearing Off Symptoms Occurring No Earlier Than 4 Hours After Their Most Recent Levodopa/Carbidopa Dose (COMTAN) Novartis Pharmaceuticals Corporation. 1999-2000. Randomized, Double-blind, Placebo-controlled, Parallel-group, 6-month Safety, Efficacy, and Neuroimaging Trial of AMG-474-00 in the Treatment of Patient with Parkinson’s Disease. (Protocol 20000105) Amgen, Inc. 2000-2002 A Randomized, Double-Blind, Placebo-Controlled Study toEvaluate the Pharmacokinetics, Tolerability and Safety of CEP-1347 (50mg b.i.d.) When Administered With and Without Levodopa in Participants With Parkinson’s Disease (CEP-CIT), Cephalon, Inc. PI: Friedman. 2001-2003 A multicenter, double-blind, randomized, placebo-controlled study of ascending BID doses of Neotrofin (250mg, 500mg and 1000mg) over 12 weeks with 2 weeks’ follow up in patients with early stage Parkinson’s disease (14 weeks total) Protocol #082-2001-003. Neotherapeutics, Inc. 2001-2003 A randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-ranging, efficacy and safety study of three doses of TCH346 (1mg, 5mg and 20mg daily) in patients with early Parkinson’s disease. (Protocol CTCH346 0103) Novartis. 2002-2004 $59,080 A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients with Early Parkinson’s Disease. (Protocol C1347 204/PD/US-CA) Cephalon, Inc. (PRECEPT) PI: Friedman. 2002-2004 A Phase II multicenter, randomized, double blind, placebo controlled, parallel group, 2 year study to evaluate the effect of GPI 1485 on beta-CIT scanning and clinical efficacy in symptomatic Parkinson’s disease patients receiving dopamine agonist therapy. Guilford Pharmaceuticals. PI: Friedman. 10/02-5/06 Aripiprazole: An open label, flexible dose pilot study to evaluate the safety and tolerability of
50
50
Aripiprazole in patients with psychosis associated with Parkinson’s disease. BMS. 5/2003 – 5/2004 $117,000 APO: An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of “Off” Episodes in Patients With “On-Off” or “Wearing-Off” Effects Associated With Late-Stage Parkinson’s Disease (Mylan Pharmaceuticals, Inc. Study Number: APO401) $45,000 Dysport: Phase II, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo- Controlled Study to Assess the Efficacy and Safety of a Single Administration, By Subcutaneous Injection, of 3 Doses of DYSPORT (40 units/ eye, 80 units/eye and 120 units/eye) for the Treatment of Benign Essential Blepharospasm - Beaufour Ipsen Research & Development 11/2002 - 11/2003 $35,000 Site co-PI Inspect: Investigating the effects of short-term treatment with Pramipexole or levodopa on [123I]Beta-CIT and SPECT imaging in early Parkinson’s disease. JH Friedman site PI Kyowa: A Long Term, Multicenter, Open-Label Safety Study with Flexible Dose Range of KW-6002 as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy. March 2002 to December 2003, Kyowa Pharmaceuticals $11,000 per patient (27 patients) TEVA: A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson’s Disease (PD) Patients. JHF site PI. Jan-Dec 2003. $112,000 Mood and Sleep in Parkinson’s Disease, July 2004 to April 05. Parkinson’s
Disease research fund, Memorial Hospital of RI. (JHF co supervising geriatric research psychiatry fellow, Leora Borek,MD)
REM Sleep Behavior Disorder and Testosterone Levels in Men With Parkinson’s disease, Dec 04 to May 05, Parkinson’s disease research fund of Memorial Hospital of R.I. JHF site co PI. SAD-PD: Study of antidepressants in Parkinson’s Disease (SAD-PD), Nov 04 to December 2005. NIH grant. JH Friedman, site PI. Janssen Pharmaceuticals: A placebo controlled double blind study of galantamine in the treatment of executive dysfunction in non-demented PD patients. Investigator initiated trial. J. H. Friedman,MD PI. $122,000 July 04- (active). Boerhinger-Ingleheim: Double blind placebo controlled trial of a triple reuptake inhibitor (serotonin, norepinephrine, dopamine) for the treatment of untreated patients with PD. JH Friedman, site co-PI. 9/04-12/05. Boston Life Science: Is Altropane SPECT scanning superior to a general practitioner’s ability to distinguish Parkinson’s disease from Essential Tremor? JH Friedman, site co-PI. (10/04-12/05)
51
51
Acadia Pharmaceuticals: ACP 103 for the treatment of drug induced psychosis in Parkinson’s disease. A multi center double blind placebo controlled trial. JH Friedman, PI for the study and for the Brown site. May 04- June 06. Medical monitor for NIH trial of DBS effect on mood in Parkinson’s disease. Michael Okun, PI. $10,000 per year. 2004-2006. K23 NS044997 Novartis: Double blinded long term comparison of Stalevo vs carbidopa/levodopa as monotherapy for the treatment of drug naïve PD patients. JHFriedman site co-PI. Teva: ADAGIO (rasagaline neuroprotective trial). 10/05- JHFriedman, site PI. Glaxo-Smith-Kline: Low dose ropinerole for the treatment of drug induced akathisia in schizophrenic patients. (Investigator initiated trial). Tentatively approved with funding of $103,000. PI JHFriedman. Feb 06- Kinetics Foundation: Cross cultural validation of the Parkinson Fatigue Scale. Jan 06- (active). $5,000. JHFriedman site PI Publications of the Parkinson Study Group in which J H Friedman,
was an investigator (usually the site PI) 1. Parkinson Study Group:DATATOP. A multi-center controlled clinical trial in early Parkinson’s
disease, Arch Neurol 1989;46:1052-1060. 2. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s
disease. N Engl J Med 1989;321:1364-1371. 3. Shoulson I and the Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of
parkinsonism (DATATOP). Acta Neurol. Scandinavica (Supplement 126) 1989;80:171-175. 4. Shoulson I, Fahn S, Oakes D, Lang A, Langston JW, LeWitt P, Olanow W, Penneu JB, Tanner C.
Deprenyl for the treatment of early Parkinson’s Disease (letter). N Engl J Med 1990;322:1527-1528.
5. Jankovi J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, Stern M, Tanner C, Weiner W and the Parkinson Study Group. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. Neurology 1990;40:1529-1534.
6. Shoulson I and the Parkinson Study Group: Effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson’s disease: a preliminary report, in Neuroprotective Therapy in Early Parkinson’s Disease, UK Rinne, E Heinonen (eds.) Orion Corp, Farmos, Turku, Finland, 1991, pp 25-32.
7. Parkinson Study Group, DATATOP and clinical neuromythology IX. Neurology 1991:41:771-773. 8. Shoulson I, and the Parkinson Study Group. An interim report of the effect of selegiline (I-
deprenyl) on the progression of disability in early Parkinson’s disease. Euro Neurol 1992:32 (Suppl 1):46-53.
9. LeWitt PA, Galloway MP, Matson W, Mibury P, McDermott M, Srivastava DK, Oakes D, and the Parkinson Study Group. Markers of dopamine metabolism in Parkinson’s disease. Neurology 1992;42:2111-2117.
10. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993;328:176-183.
52
52
11. Shults CW, and the Parkinson Study Group. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson’s disease. Acta Neurol Scand Supplement 1993;87:36-42.
12. Parkinson Study Group. A controlled clinical trial of lazabemide (RO19-6327) in untreated Parkinson’s disease. Ann Neurol 1993;33:350-356.
13. Parkinson Study Group. A controlled clinical trial of lazabemide (RO19-6327) in levodopa treated Parkinson’s disease. Arch Neurol 1994;51:342-347.
14. Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter I, Huber S, Kanigan B, Landow E, Rudolph E, Rudolph A, Saint-Cyr J, Stern Y, Tennis M, Thalen J, Shoulson I and the Parkinson Study Group. The effects of deprenyl and tocopherol on cognitive performance in early untreated Parkinson’s disease. Neurology 1994;44:1756-1759.
15. Parkinson Study Group (Fahn S, primary author). Cerebrospinal fluid homovanillic acid in the
DATATOP study on Parkinson’s disease. Arch Neurol 1995;52:237-245. 16. McDermott MP Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, Golbe LI, Koller W. Lang AE,
Olanow CW, Shoulson I, Stern MG, Tanner CM, Weiner WJ and the Parkinson Study Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson’s disease. Arch Neurol 1995;52:565-570.
17. Parkinson Study Group (Shoulson I, primary author). Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 39:29-36, 1996.
18. Parkinson Study Group (Penney J, primary author). Impact of deprenul and tocopherol treatment on Parkinson’s disease in DATATOP subjects requiring levodopa. Ann Neurol 39:37-45, 1996.
19. Parkinson Study Group (Kieburtz K, primary author). Effect of lazabemide on the progression of disability in early Parkinson’s disease. Ann Neurol 40:99-107, 1996.
20. LeWitt P. Oakes D, Cui L and the Parkinson Study Group. The need for levodopa as an end point of Parkinson’s disease progression in a clinical trial of selegiline and alpha-tocopherol. Mov Disord 1997;12:183-189.
21. Richard IH, Kurlan R and the Parkinson Study Group. A survey of antidepressant drug use in Parkinson’s disease. Neurology 1997;49:1168-1170.
22. Parkinson Study Group (Kieburtz K, primary author). Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 1997;42:747-755.
23. Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C and the Parkinson Study Group. Serotonin Syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Neurology 1997;48:1070-1077.
24. Parkinson Study Group (Shoulson I, primary author). Mortality in DATATOP: A multi-center trial in early Parkinson’s disease. Ann Neurol 1998;43:318-325.
25. Shoulson I and the Parkinson Study Group. DATATOP. A decade of neuroprotective inquiry. Ann Neurol 1998;44 (Supple 1):S160-S166.
26. Vatassery GT, Fahn S, Kuskowski MA and the Parkinson Study Group. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Neurology 1998;50:1900-1902.
27. Shoulson I and the Parkinson Study Group. DATATOP. A Decade of Neuroprotective Inquiry. In: CW Olanow, P Jenner (eds). Beyond the Decade of the Brain: Neuroprotection in Parkinson’s Disease Volume 3, Wells Medical Ltd, Kent, UK, 319-329, 1998.
28. Growdon HD, Kieburtz K, McDermott MP, Panisset M, Friedman JH and the Parkinson Study Group. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson’s disease patients. Neurology 1998;50:1327-1331.
29. Parkinson Study Group (Friedman J, primary author). Low Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson’s Disease. N Engl J Med 1999;340:757-763.
30. Parkinson Study Group (Shetty N, primary author). The placebo response in Parkinson’s disease. Clin Neuropharmacol 1999;22:207-212.
31. Parkinson Study Group (Marek K, primary author). A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurol 2000, 55;1540-1547.
32. Parkinson Study Group (Factor S, primary author). Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease: Results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001;16:135-139.
53
53
33. Giladi N, McDernott MP, Fahn S, Przedborski S, Jankovic J, Stern M,, Tanner C and the Parkinson Study Group. Freezing of gait in PD: Prospective assessment in the DATATOP cohort. Neurology 2001;56:1712-1721.
34. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P,Olanpw CW, Penney JB, Tanner C, Kieburtz K, Rudolph A, Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002:51(5);604-612.
35. Pankratz N, Nichols WC, Uniacke SK, Halter C. Rudolph A, Shults K, Conneally PM, Foroud T and the Parkinson Study Group. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet 2002 71:124-135.
36. Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolpj A, Conneally PM, Foroud T, and the Parkinson Study Group. Linkage stratification and mutation analysis at the parkin locus identifies mutation positive Parkinson’s disease. J Med Genet 2002 39:489-492.
37. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC and the Parkinson Study Group. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003;60:796-801.
38. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T and the Parkinson Study Group. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Human Genet 2003;72:1053-1057.
39. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG. Kuflan R, Parsa M, Pfeiffer R and the Parkinson Study Group. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 2003;60:1756-1761.
40. Pankratz N, Nichols WC, Uniacle SK, Halter C, Murrell J. Rudolph A, Shults C, Conneally PM, Foroud T, and the Parkinson Study Group.Genome-Wide Linkage Analysis and Evidence of Gene-by-Gene Interactions in a Sample of 362 Multiplex Parkinson Disease Families. Submitted to Human Molecular Genetics.
41. Nichols, WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T, and the Parkinson Study Group. Evaluation of the Role of Nurr 1 in a Large Sample of Familial Parkinson Disease. Submitted to Annals Neurol.
42. Parkinson Study Group (Siderowf, A primary author). A controlled, randomized, delayed-start study of rasagiline in early Parkinson’s disease. Arch Neurol 2004;61:561-566.
43. Nathan Pankratz, Sean K, Uniacke, Cheryl Halter, Alice Rudolph, Clifford W. Shults, P. Michael Conneally, Tatiana Fouroud, William C. Nichols and the Parkinson Study Group influencing age of onset in Parkinson disease: replication of the PARK3 locus and identification of additional novel loci. Submitted.
44. Parkinson Study Group (Schwid S. primary author). A randomized placebo-controlled trial of rasagiline in levodopa-treated Parkinson’s disease patients with motor fluctuations (The PRESTO Study). Arch Neurol (in press).
45. Shoulson I and the Parkinson Study Group-Fahn S, Brin M, Burke R, Breessman S, Tetrud J, Langston JW, Jankovic J, Kurlan R, Plumb S, Odoroff C, Tanner C, Goetz C, Klawans H, Shannon K, Lang A, Weiner W, Sanchez-Ramos J, Penney J, Young a, Starosta-Rubenstein S, Hurtig H, Stern M, Gollomp s, Pfeiffer R, Friedman J, Olanow W, Paulson G, Tsui J, Nutt J, Rodnitzky R, Grimes D, Hassan M, LeWitt P, Hoehn M, Bennett J. Correlates of clinical decline in early Parkinson’s disease. Neurology 1987;37 (Suppl 1);278.
46. Shoulson I and the Parkinson Study Group. Antioxidative experimentation strategies for Parkinson’s disease (abstract). 9th International Symposium on Parkinson’s Disease, Jerusalem, Israel, June 5-9, 1988, p.19.
47. Shoulson I and the Parkinson Study Group. Antioxidative experimental strategies aimed at slowing the progression of Parkinson’s disease (abstract). Proceedings of the International Symposium on Alzheimer’s Disease, June 12-15. 1988, Kuopio, Finland (World Federation of Neurology Research Group on Dementia) Publications of the University of Kuopio (ISBN 951-780-488-1), 1988; pp. 35-36.
48. Shoulson I and the Parkinson Study Group. Deprenyl in early Parkinson’s disease: symptomatic versus protective efficacy (abstract). Neurology (Suppl. 1) 1990;40:153.
49. Oakes D and the Parkinson Study Group. Progression of early Parkinson’s disease until levodopa therapy is required (abstract).Neurology (Suppl. 1) 1990;40:370.
54
54
50. The Parkinson Study Group (PG Como, Presenter, Rochester,NY). Effect of Deprenyl on Neuropsychological Function in Early Parkinson’s Disease (abstract). Ann Neurol 1990;28:297.
51. Kieburtz K, Como P, McDermott M, Rudolph A, Growdon JJ, Tennis M, Brady J, Kanigan B, Saint-Cyr JA, Kierans C, Landow E, Stern Y, Thelan J and the Parkinson Study Group. Neuropsychological evaluation in early Parkinson’s disease (abstract). Ann Neurol 1990;28:236.
52. LeWitt PA, Galloway M, Oakes D, Watts A, Mattson W and the Parkinson Study Group. Homovanillic acid, other monoamine metabolites, and xanthine in parkinsonism CSF. Neurology 1991l41 (Suppl 1):379.
53. LeWitt P, Galloway M, Matson W, McDermott M, Oakes D, and the Parkinson Study Group. Markers of endogenous dopamine synthesis in Parkinson’s disease. Neurology 1992;42 (Suppl 3):421.
54. LeWitt P, Galloway M, Matson W, Milbury P, McDermott M, Oakes D, and the Parkinson Study Group. CSF studies in untreated Parkinson’s disease:dopamine metabolism and xanthine. Neurosci Abstracts 1992;18:1248.
55. LeWitt PA, Bannon M, Galloway M, Kapatos G, Matson W, McDermott M, Oakes D and the Parkinson Study Group. Monoaminergic metabolism, substance P, met- enkephalin, and biopterin metabolism in Parkinson’s disease. Neurol 1993;43:A408.
56. Shoulson I and the Parkinson Study Group. The impact of extended deprenyl treatment in patients not requiring levodopa therapy. Annals Neurol 1993;34:263.
57. Parkinson Study Group (S Fahn, primary author). The DATATOP study: cerebrospinal fluid homovanillic acid changes in patients with mild, early parkinsonism. Mov Disord 1993;8:410-411.
58. Richard I, Kurlan R, Tanner C, the Parkinson Study Group. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Neurology 1996;46:A374.
59. Parkinson Study Group (Kieburtz K, primary author). The COMT inhibitor entacapone improves parkinsonian features in fluctuating patients. Mov Disord 1996;11:268.
60. Growdon JH, Kieburtz K, McDermott M, Panisset M, Friedman JH and the Parkinson Study Group. Levodopa improves motor function without impairing cognition in mild non-demented PD patients. Mov Disord 1997;12:57.
61. Panisset M, Siderowf A, McDermott M, Kieburtz K, Friedman JH, Growdon J and the Parkinson Study Group. Baseline predictors of subsequent dementia in the DATATOP cohort. Mov Disord 1997;12:836.
62. Parkinson Study Group (Shoulson I, primary author). Clinical outcome following placebo-controlled withdrawal of deprenyl (selegiline) among levodopa-treated DATATOP subjects. Mov Disord 1997;12:838.
63. Factor SA and the Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease: results of the 12-week open label follow up in the PSYCLOPS trial (abstract). Mov Disord 1998;13(suppl 2):241.
64. Blindauer K and the Parkinson Study Group. Double-blind, placebo-controlled, dose-ranging study of the safety and tolerability of SIB-1508Y, a nicotinic receptor agonist , in early Parkinson’s disease patients. Neurology, 2000;54:A278.
65. Parkinson Study Group (Goetz G, primary author).Placebo-related improvements in motor function in early Parkinson’s disease. Ann Neurol 2000;48:433.
66. Parkinson Study Group (S. Fahn,presenter). Rotigotine transdermal SysTem (SPM-962) is safe and effective as monotherapy in early Parkinson’s disease (PD) (abstract). XIV Int’l Congress on Parkinson’s Disease, July 27-August 4, 2001, Helsinki, Finland, in Parkinsonism & Related Disorder, J WFN Research Committee on Parkinsonism and Related Disorders.
67. Parkinson Study Group (K Kieburtz, presenter). Efficacy and safety of rasagiline as monotherapy in early Parkinson’s disease (abstract). XIV Int’l Congress on Parkinson’s Disease, July 27-August 4, 2001, Helsinki, Finland, in Parkinsonism & Related Disorder, J WFN Research Committee on Parkinsonism and Related Disorders.
68. Parkinson Study Group (KA Blindauer, presenter). Defining responder status in a clinical trial of the rotigotine transdermal system (SPM-962) in early Parkinson’s disease. Mov Disord 2001;16:981-982.
69. Parkinson Study Group (ND Pankratz, presenter). Genome screen to identify loci contributing to the susceptibility for Parkinson’s disease. Neurology 2002 58(Suppl 3):A111.
55
55
70. Parkinson Study Group (WC Nichols, presenter). Stratification by linkage rather than age of onset identifies more Parkin mutation positive, PD families. Neurology 2002;58(Suppl 3): A409-410.
71. Parkinson Study Group (K. Marek, presenter). Assessment of CEP-1347 Interaction with b-CIT Striatal Uptake in Parkinson’s Disease. Mov Disord 2002;17(Suppl.5):S167.
72. Parkinson Study Group (T Faroud, presenter). Identification and characterization of Parkin mutation among later-onset familial Parkinson’s disease subjects. Accepted for presentation at the American Neurological Association 127th Annual Meeting, New York City, October 2002.
73. Parkinson Study Group (S Fahn, presenter). Results of the ELLDOPA earlier vs later levodopa) study. Mov Disord 2002;17:Suppl 5, S13.
74. Parkinson Study Group (S Fahn, presenter). Does levodopa slow or hasten the rate of progression of Parkinson’s disease? The results of the ELLDOPA trial. Neurology 2003;60: A80-81.
75. Parkinson Study Group (N Pankratz, presenter) PARK3 and PARK7 linked to age of onset of Parkinson’s disease. Neurology 2003;60:A127.
76. Parkinson Study Group (WC Nichols, presenter) Lack of association of homozygosity for the 7048G7049 intron six nurr 1 gene polymorphism in 322 families with Parkinson’s disease. Neurology2003;60:A 281-282.
77. Fahn S, Parkinson Study Group. Evaluation of the long-duration benefit from levodopa: Results from the ELLDOPA (Earlier vs. Later) LevoDOPA) Study. Mov Dis 2003:18(9)1085-1086.
78. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudoph A, Shults CW, Conneally PM, Foroud T, Parkinson Study Group. Evidence for a gene on chromosome 10 that influences both PD and AD susceptibility. Neurol 2004;62( Suppl 5):A27/
